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MAGNETIC NANOPARTICLES IN NANOTECHNOLOGY  
 
Nanotechnology has revolutionized many branches of cience and is generally regarded as 
one of the most promising future technologies, due to its broad scope of potential 
applications. One general advantage of nanotechnology is its versatility to modify physical, 
chemical and biological properties of materials when r aching nanoscalar dimensions. 
Commonly, sizes of approximately 1 – 100 nm in diameter are regarded as relevant. One of 
the subfields in which nanoparticulate objects have found application is nanomedicine. As 
various biological processes occur at the nanometer scale, they can be easily accessed or 
manipulated by nanoparticles [1]. In combination with their unique physicochemical 
properties, nanoparticles offer interesting features for drug delivery and diagnostic purposes. 
Advances in materials science further contribute to the development of improved carriers for a 
more specialized treatment and diagnosis of disease [2]. The motivation for these structural 
refinements is to approximate the idealized concept of ‘magic bullets’ proposed by Paul 
Ehrlich, who envisioned a pharmaceutical agent selectively targeting abnormalities inside the 
body with no side effects. Apart from the quest for specificity, nano science is attempting to 
provide nanoparticles with additional functionalities, such as traceability or susceptibility to 
external triggers. 
Magnetic nanoparticles (MNP) represent a class of carriers with inherent functionality. Due to 
the multitude of physical processes inducible in these carriers, MNP have gained considerable 
interest among the broad spectrum of nanoscale materials for biomedical use [3]. The effects 
mediated by intrinsic magnetic properties range from heat generation to magnetic attraction 
and tissue proton relaxation. This versatility of action renders MNP highly suitable for 
numerous applications, including hyperthermia, magnetic resonance imaging (MRI) and 
(image-guided) drug delivery. As regards biomedical applications, MNP are usually 
administered orally or intravenously in the form of stable ferrofluidic nanosuspensions [4]. 
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These nanoparticles are composed of magnetic iron or ferrite cores surrounded by organic or 
inorganic coatings and, optionally, drug or targeting molecules. In general, the complexity of 
the modular design of MNP is dependent on the desired application. Several routes have been 
described for the synthesis of magnetic cores, each wit  a different impact on size, 
crystallinity and morphology of the generated nanoparticles [5]. Subsequent or concomitant 
addition of stabilizers is a crucial step, as these molecules provide size control, stabilization in 
aqueous environments and the possibility for further functionalization [6]. In the majority of 
cases, the resultant assembly is comparable to a core-shell structure. This dual design involves 
MNP being recognized as ‘usual’ nanoparticular vehicl s from the outside while carrying an 
internal functionality. These considerations are rel vant to the prediction of biodistribution 
processes upon administration of MNP. 
 
 
BIODISTRIBUTION AND TARGETING  
 
Nanoparticles have to overcome a number of physiological barriers before reaching the site of 
action. In the case of intravascular administration, nanoparticles are confronted with ample 
plasma-protein levels, blood cells and high ionic strength of the bloodstream [7]. Apart from 
aggregation of nanoparticles, extensive attachment of plasma proteins and subsequent 
removal by phagocytic cells can occur. The latter effect is a function of both particle size and 
surface texture, and by appropriate manipulation of these parameters, blood circulation times 
and access to deep compartments can be significantly e hanced [8]. Where MNP are 
concerned, the impact of size could be demonstrated for ultrasmall superparamagnetic iron 
oxide nanoparticles (USPIO), which display enhanced plasma half-life, and are thus capable 
of extravasating to a larger extent from the blood vessels into interstitial spaces [9]. 
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In addition, the biodistribution of nanoparticles is largely dependent on the morphology and 
accessibility of certain tissues. Targeting effects can contribute to a preferential accumulation 
of pharmaceutical agents inside cancerous areas of the body. Passive targeting exploits the 
characteristic features of tumor biology, which allow nanoparticles to concentrate in the tumor 
by the enhanced permeability and retention (EPR) effect [10]. This effect describes the 
facilitated entrance and enhanced residence of nanosc led particles in tumor tissues, due to 
the defective vasculature and dysfunctional lymphatic drainage of tumors. The degree of drug 
accumulation generally varies with tumor size, vascular maturation and endothelialization 
heterogeneity of tumor blood vessels [11].  
  
 
Figure 1. Passive tumor targeting: Long-time confinement of pharmaceutical nanocarriers 
inside vessels with intact vasculature (top), and facilitated extravasation of such carriers due 
to fenestrated tumor vasculature (bottom) [12]. 
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As passive targeting suffers from several limitations, including EPR restriction to specific 
tumors and random nature of the approach, the need for more selective strategies has 
emerged. Active targeting involves the attachment of recognition molecules to the surface of 
nanoparticles, in order to achieve maximum binding to target cell receptors [13]. There are 
different classes of potential recognition molecules, including antibodies, proteins, small 
molecules and aptamers [14]. Consequently, tumor binding and internalization are 
significantly enhanced at the desired site of action. 
The principles of active and passive targeting can also be transferred to magnetic 
nanoparticles. As stated above, MNP for biomedical applications usually carry polymer 
shells, so that their interaction with cellular components of the body is highly comparable to 
polymeric drug delivery vehicles. Consequently, theperformance of MNP is associated to 
both external factors, such as size and surface texture, and internal factors like magnetism and 
crystallinity [15]. Depending on the choice of application for MNP, different aspects of 
targeting have priority. While passive distribution f the MNP formulation throughout the 
body is in most cases sufficient for imaging purposes, active targeting strategies are desirable 
for drug delivery and hyperthermia purposes. In this context, biodistribution experiments are 
often helpful for the prediction of accumulation and effectiveness of nanocarriers. A 
convenient method to measure pharmacokinetic distribution profiles of magnetic 
nanoparticles is radiolabeling [16]. 
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APPLICATIONS IN BIOMEDICINE  
 
Magnetic nanoparticles in drug delivery and hyperthermia 
Drug delivery designates the method or process of administering a pharmaceutical compound 
to achieve a therapeutic effect in humans or animals [17]. The classical efforts of magnetic 
drug delivery included the targeting of drug-loaded MNP by means of a strong external field. 
Due to the limited depth effect of permanent magnets, this method is becoming increasingly 
irrelevant [18]. In this context, the near-surface treatment of physical defects constitutes an 
exception. For example, studies for the intraarticular retention of magnetic particles in the 
presence of an external magnet have shown promising results. Implantation of permanent 
magnets close to the site of action is another possibility of circumventing the depth limitation 
[19]. Moreover, very strong magnetic field gradients can be used to manipulate MNP in 
deeper body regions [20]. The more popular approach f image-guided drug delivery will be 
discussed in a later section.     
Magnetic hyperthermia is a treatment modality for cancer, which exploits the high efficiency 
of superparamagnetic crystal suspensions to absorb energy in an oscillating magnetic field 
and transform it into heat [21]. Depending on the induced temperature and the duration of 
heating, the therapy either results in direct death of tumor cells, or makes the cells more 
susceptible to concomitant radiotherapy or chemotherapy [22]. Healthy tissues can tolerate 
elevated temperatures for longer periods because of their intact thermoregulation. Further 
protection of healthy cells can be achieved by the dir ct local application of MNP into the 
tumor tissue. The heat dissipation of MNP results from the parallel contributions of thermal 
and viscous rotation upon oscillation of a magnetic field [23]. The energy release is dependent 
on both particle size and polydispersity of the excit d material, and is given as specific 
absorption rate (SAR) [24]. Studies with targeted magnetic nanoparticles are still restricted to 
the in vitro stage, due to the insufficient level of accumulation at the site of action [25]. In 
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contrast, localized administration of magnetic ferrofluids by means of minimally invasive 
surgery is currently being studied for a number of applications, either as single or synergetic 
therapy [26]. In 2010, the medicinal products NanoTherm® and NanoActivator® (MagForce 
Nanotechnologies) have found EU approval for the treatment of glioblastoma multiforme 
[27].  
 
Applications in magnetic resonance imaging 
The application of magnetic nanoparticles as MRI contrast agents aims at the improved 
depiction of somatic structures. MNP have the potential to accentuate signal intensity 
differences between adjacent tissues in MRI experiments. The concurrent contrast 
enhancement is attributable to their unique relaxometric properties. In scientific literature, 
MNP for imaging purposes are often referred to as superparamagnetic iron oxide 
nanoparticles (SPION and USPIO) [28]. These nanoparticles accumulate in the cells of the 
mononuclear phagocytic system upon administration. Depending on their location after 
uptake, these agents can serve as MRI markers for liver and spleen imaging, lymph node and 
blood pool imaging [29].  
 
       
Figure 2. MRI detection of breast cancer metastasis in a liver segment before (left) and after 
(right) application of SPION contrast agents. Improved delineation of metastasis (black 
arrows) and liver lesions (white arrows) is observable after SPION administration [30]. 
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Classical SPIONs are not suitable for tumor visualization because of insufficient 
accumulation at the tumor site. The need for contrast gents with pronounced tumor 
selectivity has led to the development of modern SPIONs combining previous features with 
active targeting principles (Table 1). 
 
Table 1. Targeting strategies for magnetic nanoparticles: name of targeting moieties, cellular 
targets and therapeutic application. 
 
Depending on their composition, targeted nanocarriers are able to locate a large number of 
structures. The possibility of tailoring MNP in such a way that they can track down a defined 
molecular target concurs with the idea of molecular imaging [31]. In addition to structural 
refinements, the performance of MNP can be upgraded by introducing further functionalities, 
for example, therapeutic payloads and secondary imaging agents. Drug-loaded MNP are used 
to monitor drug accumulation at the desired site of action or to trigger drug release, hence the 
expressions image-guided drug delivery and theragnostics [32]. The bound agents are in most 
cases chemotherapeutics or radiotherapeutics for cancer therapy. In recent years, stem cell 
Name Target Imaging application Reports 
Folic acid Folate receptor Breast cancer [34] 
RGD mimetic ανβ3 integrin Integrin-positive cell imaging [35] 
PBP P-selectin Post-stroke neuroinflammation [36] 
RGD peptide ανβ3 integrin Breast cancer [37] 
EGFRvIII antibody EGFRvIII Glioblastoma multiforme [38] 
anti-HER2 affibody HER2/neu Breast cancer [39] 
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therapy has attracted much attention, due to its healing potential for incurable diseases. The 
fate of administered stem cells can be tracked after ex vivo labeling with MNP. Meanwhile, 
the concept of cell tracking has been expanded to xen grafts, among others [33]. 
 
Future developments 
Over the past decade, the concept of multimodality in vivo imaging has emerged. The term 
describes the combination of two or more imaging modalities complementing each other, 
usually within the setting of a single examination. Among the applied modalities are MRI, X-
ray computed tomography (CT) and single-photon emission computed tomography (SPECT). 
Contrast agents suitable for multimodality in vivo imaging must be responsive to the chosen 
modalities and have to meet strict requirements, including sustained detectability of signal, 
lack of interference and uniformity of signal ratio [40]. The confinement of two 
functionalities in one nanocarrier enables dual imaging following a single administration. 
Standard nanosystems for MRI and optical imaging containing iron oxide and Cy5.5 are, for 
example, used for precise surgical procedure planning [41]. In short, the challenge to generate 
tailored contrast agents for multimodality in vivo imaging is substantial. 
 
 
PHYSICAL PRINCIPLES OF MAGNETISM  
 
The first studies on the phenomenon of magnetism date b ck almost three thousand years, but 
it was not until the nineteenth century that scientists made enormous progress in the 
understanding of the physical principles which underlie magnetism. Among the most 
important findings were on the one hand the direct linkage of magnetism and electricity, on 
the other hand the atomistic rather relativistic explanation for magnetic effects. Magnetism is 
a cooperative phenomenon which involves the interplay of huge numbers of particles. Thus, 
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the magnetic behavior of macroscopic systems is not restricted to the individual state of 
intrinsic isolated magnetic moments, because also their order and mutual interactions 
contribute to the overall effect [42].  
In this section, the most relevant mechanistic principles and forms of magnetism are 
introduced, as they present the base for the phenomn of superparamagnetism, which is of 
major interest in this work. 
 
Magnetic moments and magnetization 
The magnetic moment is the fundamental quantity in magnetism. If an electric current I 
circulates around an infinitesimal oriented loop of area dA, then a magnetic field is generated 
normal to the loop plane with a resultant magnetic moment dµ given by 
dAId =µ  .     (Eq. 1) 
Due to the fact that a loop of finite size presents nothing else than a giant assembly of equal 
infinitesimal current loops distributed throughout its plane, the overall magnetic moment µ of 
such loops can be calculated by the integration of the generated minuscule moments dµ: 
∫ ∫== dAIdµµ  .         (Eq. 2) 
The appearance of magnetic moments in atoms is associ ted with both the orbital motion of 
electrons around the nucleus and their tumbling spin rotation around their own axis. Both 
types of movement influence the angular momentum L of the electrons and go along with a 
transport of current, thereby creating a magnetic moment. According to quantum theory, all 
angular momenta appearing in atoms are quantized, in such a way that their values are either 
integral or half-integral multiples of the quantity h/2π (= h ), where h is Planck’s constant. 







=µ  .     (Eq. 3) 
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For an electron with m = me and q = −e which revolves around the nucleus of a hydrogen 






 ,         (Eq. 4) 






hµ  9.27 x 10-24 Am2 .   (Eq. 5) 
The Bohr magneton is the smallest entity of the magnetic moment, and by convention a 
convenient unit for describing the overall size of atomic magnetic moments. Inside a magnetic 
solid, a large number of atoms with magnetic moments is present. The magnetization M 
represents the common descriptor for magnetic systems at the macroscopic scale, and is 
defined as the magnetic moment per unit volume. The magnetization M can be imagined as a 
vector field which is continuous throughout homogeneous materials, except for their edges. 
 
Magnetic field and magnetic susceptibility 
The physical quantities of the magnetic field H and the magnetic induction B are linked under 
vacuum conditions via the permeability of free space µ0: 
HB 0µ= .     (Eq. 6)  
Inside magnetic materials, the relation between both quantities is complicated by the 
contribution of the intrinsic magnetization M, so that the abovementioned equation has to be 
expanded to 
HHHHMHB rµµχµχµµ 0000 )1()()( =+=+=+=  ,  (Eq. 7) 
where χ is the magnetic susceptibility and µr = 1 + χ is the relative permeability of the 
respective material. The parameter χ describes the degree of magnetization of a substance in 
response to an applied field.  
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Depending on the material type, the susceptibility χ takes characteristic values which are 
indicative of a certain class of magnetic behavior: 
Diamagnetism  χ  negative, |χ| ≪ 1 
Paramagnetism χ  positive, |χ| ≪ 1 
Ferromagnetism χ  positive, |χ| ≫ 1 . 
Diamagnetic and paramagnetic materials exhibit magnetic susceptibilities close to zero, and 
consequently only weak responses to external fields. In contrast, ferromagnetic effects are 
rather large, able to produce magnetizations orders of magnitude greater than the applied field 
[43]. The reason for this striking discrepancy lies in the state of order: while materials from 
the first two groups can be regarded as assemblies of i olated, non-interacting magnetic 
moments, ferromagnets display long-range magnetic order, leading to strong cooperative 
forces (below a certain critical temperature). Furthe  ground states with highly ordered 




Diamagnetism is an inherent additive effect of all materials, but it only constitutes the 
predominant role for substances containing atoms or molecules with filled electronic shells. 
The application of a magnetic field causes the induction of a magnetic polarization, which 
opposes the original field and therefore weakens the magnetic induction B inside the material 
(χ < 0). This is in accordance to Lenz’s Law, which claims that the triggered back 
electromotive force on charge carriers acts antidirectional to the magnetic field [44]. It is 
noteworthy that all materials undergo this orbital response. However, in paramagnetic and 
ferromagnetic substances, this rather weak effect is overwhelmed by the existence of major 
permanent magnetic moments caused by unpaired electrons. Perfect diamagnets with 
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Figure 2. Behavior of diamagnetic (left) and paramagnetic (right) solids in a homogeneous 
magnetic field. A diamagnetic substance is repelled from the magnetic field, due to induction 




When paramagnetic materials are introduced into an external magnetic field, an enforcing 
magnetization parallel to the existing field is induced. Atoms of paramagnets contain unpaired 
electrons, and thus permanent non-zero magnetic moments which tend to either randomize 
and be statistically distributed at zero field conditions, or line up with an applied field. For the 
latter case, a net magnetization M becomes measurable which depends on both the field 
strength B and the temperature T. Thermal agitation counteracts the alignment, whereas high 
field magnitude favors it. The magnetization of a cl ssical paramagnet is described by the 
Langevin function, 
L(x)  =  
SM
M
 =  coth x – 
x
1





 ,   (Eq. 8) 
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where kB is the Boltzmann constant and MS is the saturation magnetization, which is the 
maximum detectable magnetization at complete alignment of all moments.  
For small magnetic fields, Curie’s Law states the inverse proportionality of magnetic 
susceptibility and temperature. 
 
Ferromagnetism 
The special arrangement of magnetic moments inside ferromagnets explains their unique 
properties. Ferromagnetic systems are composed of domains which in turn enclose magnetic 
moments of parallel orientation. The unidirectional alignment of moments is a consequence of 
the exchange interactions between identical particles, and can be predicted by quantum 
mechanical calculations [44]. Despite the fact that e ch domain is thus magnetized until 
saturation, untreated ferromagnets do not appear to be magnetic at the macroscopic scale, 
which is due to the transient change in domain orientation and the resultant cancellation of 
moments.  
Upon application of a magnetic field, several processes including domain wall motion, 
domain rotation and coherent domain rotation all lead to the gradual alignment of magnetic 
moments with the external field, and give rise to a strong net magnetization. This 
magnetization M increases with the field strength H and experiences saturation (MS) at 
complete orientation of all magnetic moments with the field (Figure 3). When the field is 
reset to zero, the system maintains a remanent magnetization MR and behaves like a 
permanent magnet. In order to entirely demagnetize the system, a coercive field HC of 
opposite sign needs to be applied. Both parameters d termine the course of the associated 
hysteresis loop, which encloses an area equivalent to the energy loss by heat dissipation 
during the magnetization cycle. 
The quantity MR and the hysteresis area are also measures for the reluctance of a material to 
the reversal of magnetic moments after uniform magnetization. Large hysteresis areas occur 
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when the mechanism of domain wall rotation is efficiently hindered, due to pronounced 
anisotropic effects or dislocations in the crystallographic structure. Corresponding materials 
are called ‘magnetically hard’ and find, among others, application as data storage media due 
to these unique features. It should also be noted that ferromagnets lose their structured 
orientation above a critical temperature, the Curie temperature, and then act like paramagnets. 
 
 
Figure 3. Hysteresis loop for a ferro- or ferrimagnetic substance. Magnetic saturation (MS) is 
accomplished at high magnetic field strengths, due to complete alignment of magnetic 




Ferrites, for which this phenomenon was initially described, and garnets belong to the family 
of ferrimagnets. The domains of these systems can be imagined to be composed of two 
interpenetrating sublattices bearing magnetic moments of antiparallel alignment. Unlike in 
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antiferromagnets, the different magnitude of opposed moments or their non-equivalent 
distribution among the compartments result in the appe rance of spontaneous magnetization. 
 
         
Figure 4. Schematic composition of antiferromagnetic (left) and ferrimagnetic (right) 
materials. The system assemblies can be considered as two interpenetrating sublattices with 
opposite alignment of magnetic moments. In antiferromagnets, the magnetic moments of the 
sublattices are equal and therefore cancel out [42].  
 
Considering further the partitioning into domains, it is not surprising that the magnetization 
dependence on the field very much resembles that of ferromagnets. The same applies for the 
influence of temperature, with the exception that some ferrimagnetic materials exhibit a 
compensation temperature at which the two sublattices gain equal moments. 
Ferrites are compounds of the basic chemical formula MO·Fe2O3 where M is a divalent cation 
like Zn2+, Fe2+, Mn2+, Ni2+, Cu2+ or Co2+. Magnetite (Fe3O4) and the related defect crystal 
maghemite (γ-Fe2O3) are part of this group, and their structures are bri fly highlighted due to 
their relevance for the experimental section. The general spinel structure contains two types of 
lattice sites, namely tetrahedral (or A) sites and octahedral (or B) sites. Cations of the A 
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sublattice are surrounded by four oxygen neighbors, while B site cations are coordinated by 
six oxygen atoms. 
 
Figure 5. Ferrimagnetic coupling of magnetic moments i  a spinel. The orientation of the 
moments is parallel in each sublattice and antiparallel between the sublattices [43]. 
 
Magnetite forms an inverse spinel in which Fe2+ ions occupy half the B sites, while the Fe3+ 
ions sit at the other half of the B sites and all the A sites [45]. With all the octahedral moments 
aligned in parallel fashion, due to superexchange it ractions, and the tetrahedral moments 
pointing to the antiparallel direction, an approximation for the saturation magnetization of the 
formula unit can be given substractively in multiples of the Bohr magneton: 2 (0.5 · + 0.5 · 
4) µB – 5 µB = 4 µB. The factor 2 is explained by the existence of twice as many B sites as A 
sites in the crystal. The structure of maghemite is very similar and often represented by the 
formula Fe3+8 (Fe
3+
13 1/3 Fe 2 2/3) O32. This means that only trivalent iron is present in he 
crystal lattice and that vacancy ordering occurs at the octahedral sites where statistically only 
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13 1/3 sites are occupied. The saturation magnetization per formula unit of maghemite 
amounts to 2.5 µB.  
 
Superparamagnetism 
The formation of domains in ferro- and ferrimagnetic materials is driven by energetic 
considerations. Although the introduction of domain walls costs energy, the associated saving 
in magnetostatic energy renders it favorable. This equilibrium shifts when the sample 
dimensions are reduced, and below a critical diameter Dc the material consists of a single 
domain [46]. Inside particles of single-domain size, the magnetization is forced to lie along 
so-called easy axes due to magnetocrystalline and shape anisotropy reasons. In order to flip 
the magnetization between these preferred directions, a  energy barrier ∆E has to be 
overcome, which depends on the effective anisotropy c nstant Keff and the particle volume V: 
VKE eff=∆  .         (Eq. 9) 
For nanoscale objects, the energy barrier is small in comparison to the thermal energy kBT and 
the magnetization can fluctuate easily. In case kBT ≫ Keff V, the systems behave like 
paramagnets with giant non-interacting magnetic moments, hence the expression 
superparamagnetism [47]. The reversal time τ of the magnetic moments is given by the Néel-
Brown expression 









eff  ,          (Eq. 10) 
where τ0 is typically 10-9 s. If the reversal time is much longer than the observational time of a 
laboratory experiment, the magnetic moments of the system appear to be locked in a certain 
direction. This macroscopic blockade is maintained b low the blocking temperature TB which 
separates the blocked from the superparamagnetic sta e. Apart from its dependence on particle 
size, effective anisotropy constant and measuring time, TB is also manipulated by the applied 
 Chapter 1 19 
 
 
field. The field lowers the energetic barrier for mo ent reversal, and thus the blocking 
temperature.  
     
Figure 6. Temperature influence on the magnetic behavior of superparamagnetic materials. 
Below the blocking temperature TB (left), single-domain magnetic moments are blocked. 
Increase of temperature above TB (right) leads to reversal of the magnetic moments at time 
scales shorter than the experimental time. 
 
Particles for biomedical applications are usually fabricated in such a way that their moments 
are available in the superparamagnetic state at room temperature. Then, the application of a 
field will align the strong magnetic moments and result in a designated effect. Moreover, the 
absence of any remanent magnetization upon removal of the field prevents the aggregation of 
the carriers, and turns them into perfectly switchable devices. 
 
Magnetization measurements 
Experimental techniques for examining the magnetic properties of solids are numerous. 
Basically, these techniques differ with regard to their working principle and their sensitivity. 
Two devices most frequently used are the vibrating sample magnetometer (VSM) and the 
SQUID magnetometer. Both methods are based on the recording of an induction effect caused 
by the movement of a magnetic sample [48]. 
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In a VSM, a sample vibrates sinusoidally up and down, and thereby induces an alternating 
current in a stationary pick-up coil. The induced signal is proportional to the magnetic 
moment of the sample and has the same frequency as the vibration pulse. Therefore, it can be 
easily filtered out by a lock-in amplifier fed with a vibration reference signal. SQUID 
(superconducting quantum interference device) magnetom try is one of the most sensitive 
techniques for the determination of magnetic dipoles. Initially, the alteration of the magnetic 
flux upon movement of a magnetic sample along the axis of a superconducting pick-up coil is 
registered. This flux information is then transferred via a coupling coil to the central 
component of the magnetometer, namely the SQUID sensor. The sensor completes the 
transformation of the flux signal into an electrical voltage. A dc-SQUID consists of a 
superconducting ring which is interrupted at two positi ns by Josephson junctions. When the 
intrinsic current in the respective halves of the ring is affected by a change in the magnetic 
flux, a voltage drop becomes detectable at the conta ts. Magnetic fields as small as 10-15 T 
can be measured with modern SQUID magnetometers [49].    
The most direct information on the arrangement of magnetic moments inside a specimen can 
be achieved by neutron diffraction. The wavelength of neutrons is related to their velocity and 
can be tuned thermally to values similar to atomic spacings. Incident neutron beams are 
scattered on the one hand by atomic nuclei (nuclear sc ttering) and on the other hand by 
variations in the magnetic field (magnetic scattering). This is somewhat surprising, since 
neutrons do not interact with electron clouds due to their zero charge. In fact, the magnetic 
scattering is brought about by the coupling of atomic agnetic moments with those of 
neutrons. Various events can be revealed by the record d diffraction patterns: the 
magnetization of a sample results in additional peaks, while a change in strength of magnetic 
order causes a change in amplitude. Moreover, neutron diffraction can be applied to determine 
the arrangement of magnetic moments in an ordered crystal [42]. Despite all these 
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possibilities, the acceptance of this method is rather cautious, due to the fact that neutron 
generation is very expensive. 
 
 
PRINCIPLES IN MAGNETIC RESONANCE IMAGING (MRI)  
 
Atomic nuclei of non-zero spin configuration also carry magnetic moments. However, these 
moments are negligibly small in comparison to those f lectrons. Sensitive techniques, such 
as magnetic resonance imaging (MRI), are able to deect such faint nuclear moments via 
excitation under resonance conditions. MRI represents a noninvasive imaging routine for the 
detailed visualization of body structures, and is particularly suitable for the high-contrast 
depiction of soft tissues. Selective focusing during the recording procedure enables the 
production of sectional images of the area of interest. The individual pictures are finally put 
together to yield three-dimensional models of the investigated zone. A further benefit is that 
MRI involves no ionizing radiation. The scientists and later Nobel Prize winners Paul C. 
Lauterbur and Sir Peter Mansfield extended the ideas of nuclear magnetic resonance for 
imaging purposes, and were leading in the development of MRI. The central role in clinical 
MRI is played by hydrogen nuclei which consist of a single proton and appear ubiquitously in 
the human body. 
The rotation of protons around their own axis, better known as proton spin, creates a 
permanent magnetic moment parallel to the rotational axis of the spins. Upon application of a 
magnetic field B0 , the magnetic moments react with a precession motion around the field at a 
characteristic Larmor frequency ω0 which is given by 
00 Bγω =  ,     (Eq. 11)  
wherein γ  is the gyromagnetic ratio. The subtle loss of energy during precession forces the 
moments to align gradually with the field, thereby creating a net longitudinal magnetization 
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MZ along the axis of the external field. By the perpendicular input of an appropriate high 
frequency pulse under resonance conditions, that is at Larmor frequency, an entire 90° 
deflection of the magnetization vector to the xy plane takes place. The precession and spin 
motion of this transverse magnetization MXY induces an oscillating current in the detector coil, 




       
 
Figure 7. Precession movement of magnetic moments in an external field B0 results in a net 
longitudinal magnetization MZ (top). After application of a high frequency pulse, the 
magnetization vector flaps to the xy plain and induces a signal in the detector coil (bottom). 
 
After removal of the high frequency pulse, the modulus of the transverse magnetization and 
thus the oscillation amplitude decrease with time, due to special relaxation mechanisms, and 
the resultant fading of the signal is known as freeinduction decay [50]. 
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The processes leading to the decay of transverse magnetization are referred to as spin-lattice 
relaxation and spin-spin relaxation. Other denominatio s are T1 and T2 relaxation, 
respectively. Spin-lattice relaxation appears due to nergy exchange between the spin system 
and the surrounding lattice. This causes a progressive realignment with the external field, and 




−−=  ,            (Eq. 12) 
where M0 is the magnetization along the external field at equilibrium state and T1 is the so-
called longitudinal relaxation time.  
Simultaneously, spin-spin relaxation weakens the transverse magnetization by dephasing of 
the spins. The loss of phase coherence can be attributed primarily to the energy exchange 
among the spins, which is known as pure spin-spin interaction, but it can also be due to 
constant inhomogeneities in the external magnetic field. The time constant T2 for the pure 




−−=  ,            (Eq. 13) 
where MXY’ is the maximum magnetization in transverse direction. In case the contribution of 
field inhomogeneities cannot be eliminated, the time for the relaxation process is generally 
shortened and expressed as transverse relaxation time T2* . 
As T2 relaxation is a much faster process than T1 relaxation, the observed signal loss after a 
single high frequency pulse is dominated by the transverse dephasing. However, when 
multiple excitations are performed during a measurement cycle, the weighting between these 
parameters can be shifted [50]. In this connection, the settings of both the repetition time TR 
and the echo time TE of a measurement sequence have a strong impact. The quantity TR is 
defined as the time interval between two consecutive excitations of a section of interest. In 
order to attain a so-called T1 weighting, that is the assessment of contrast due to the different 
longitudinal relaxations of certain tissues, the repetition time should be kept rather small. 
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After a short TR , the magnetization vectors MZ of different tissues accessible for further 
excitations vary the most, and consequently, the highest possible contrast of signals is 
achieved. 
The echo time TE specifies the time range between excitation and registration of the MR 
signal. The later the registration happens, the more pronounced the differences in spin 
dephasing for the investigated tissues due to unequal T2 relaxation times. Therefore, the type 
of image acquiration with a combination of long repetition time and long echo time is called 
T2-weighted. In contrast, T1 weighting is accomplished by small values of TR and TE. A 
typical set of scan parameters for a T2-weighted sequence would contain a repetition time TR 
between 3000 and 5000 ms and TE in the range of 80 to 150 ms. [51]  
The choice of the MRI sequence is sometimes crucial for the detection of malignant masses 
[52]. This is because the differences in absolute signal values are dependent on the respective 
sequence, but have to be maximal for the tissue areas examined, in order to allow for 
sufficient contrast and distinguishability. 
Spin echo sequences are a method to eliminate the abovementioned magnetic field 
disturbances and their influence on the spin relaxation behavior, respectively. After standard 
excitation with a 90° pulse, the signal decays due to spin dephasing. A second 180° inversion 
pulse reverses the spins in the xy plane, whereupon they start to rephase again. Complete 
phase coherence is obtained after TE , and the amplitude swelling of the echo signal is a 
measure for the pure spin-spin relaxation (Figure 8).     
As already pointed out, the selection of the pulse sequence is a major factor affecting image 
contrast in MRI studies. The contrast is further determined by the individual physique of the 
patients, the technical specifications of the scanning device and the effect of MRI contrast 
agents. 






Figure 8. Timing of RF pulses and signal of detector il during MRI spin echo sequence 
(upper chart). The spin echo effect (lower chart): (a) The equilibrium magnetization initially 
lies along the z-direction. (b) Magnetization precession in the xy plain after 90° pulse (t = 0). 
(c)(d) Gradual spin dephasing because of field inhomogeneities. (e) Spin reversal and 
beginning rephasing after application of 180° pulse (t = τ). (f) Complete rephasing of spins at 
t = 2τ - spin echo signal [42]. 
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MRI CONTRAST AGENTS  
 
Contrast agents are a group of pharmaceuticals used to nhance the visibility of internal body 
structures, and to elaborate faint differences in the signal intensity of adjacent tissues. In 
general, the brightness (or darkness) of a tissue results additively from its proton density and 
its resonance behavior. While the first item is rather difficult to manipulate, the relaxation 
properties can be altered by means of most contrast enhancers. This is due to the generation of 
local magnetic fields which interact with the surronding protons. For paramagnetic MRI 
contrast agents, the interaction is a combination of i ner- and outersphere relaxation, whereas 
the latter mechanism dominates for superparamagnetic agents [6]. Outersphere relaxation is 
mediated by the movement of water protons in the vicinity of the generated magnetic field 
gradients, and has a strong effect on the transverse r laxation.  
On this basis, MRI contrast agents are classified into positive and negative contrast enhancers. 
Paramagnetic agents mainly accelerate the longitudinal T1 relaxation and cause a hypersignal 
in the region of interest. Due to this brightening effect, they are called positive contrast 
agents. In contrast, superparamagnetic formulations nduce rapid spin dephasing and thus 
massive shortening of the T2 relaxation time [53]. Tissues containing minimum levels of these 
agents appear darker in appropriate sequences. Therefore, such agents are also referred to as 
negative contrast agents. 
Most positive contrast agents contain the paramagnetic gadolinium ion in chelated form. The 
attachment of strong chelators reduces the toxic potential of gadolinium, and permits the 
intravasal application of the complex solutions. The indications for gadolinium complexes 
range from whole-body imaging and angiography, to the detection of focal liver lesions. 
Several marketed products have been approved by the FDA, such as Omniscan® and 
Magnevist®. 
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Nanosuspensions of superparamagnetic iron oxide modifications have found application as 
negative contrast agents in the past decade (Table 2). The approved ferrofluids contain 
magnetite or maghemite nanoparticles of different dimensions, which are surrounded by 
macromolecular stabilizers. The surface coverage with these molecules prevents the particles 
from aggregation, and optionally enables the prolongation of blood residence time, due to the 
hindrance of plasma protein opsonization. Depending o  their size, the coated nanoparticles 
tend to accumulate in different compartments of the body. While nanoparticles of very small 
dimensions (< 40 nm) concentrate in the lymph nodes after 24 hours, larger nanoparticles of 
around 100 nm are rapidly taken up by the reticuloend thelial system. As sufficient tissue 
enrichment is necessary for effective contrast enhancement, the indications follow from the 
respective pharmakokinetic distributions in the body. 
        
APTMS : [3-(2-Aminoethylamino)propyl]trimethoxysilane 
Table 2. Marketed contrast agents based on magnetic iron oxide nanoparticles. 
Trade name Manufacturer Specifications Indication Dosage 
Endorem® Guerbet S.A. Fe3O4 / Dextran 
11.2 mg [Fe] per mL 
Liver lesions 15 µmol [Fe] per kg 
body weight 
 
Lumirem® Guerbet S.A. Fe3O4 / APTMS 
0.18 mg [Fe] per mL 
GI tract, bowel 
delineation 
600 – 900 mL (oral) 
300 – 600 mL (rectal) 
Resovist® Bayer 
Schering 
Fe3O4 / γ-Fe2O3 / 
Carboxydextran 
0.5 mmol [Fe] per 
mL  
Liver lesions 0.45 – 0.7 mmol [Fe] 
(intravenous) 
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MANUFACTURING TECHNIQUES  
 
Several procedures for the fabrication of magnetic nanoparticles are available nowadays [5]. 
The selection of the appropriate synthesis route is a crucial step, due to the fact that it affects 
composition, shape and crystallinity of the products. Further features directing the decision 
are the eventual application, yield and particle uniformity. The most important methods for 
synthesizing nanoparticles of the iron oxide species Fe3O4 and γ-Fe2O3 are aqueous 
coprecipitation and thermal decomposition (Table 3).  
Coprecipitation is a convenient way to synthesize magnetic iron oxides from aqueous iron salt 
solutions by the simple addition of a base. The dimensions and the size distribution of the 
nanoparticular products can be regulated by a series of settings, among these the 
iron(II)/iron(III) ratio, type of iron salts used, pH and temperature [47]. In case the reaction is 
carried out under inert atmosphere, crystalline magnetite is formed as a product. Due to its 
susceptibility to air oxidation, magnetite is either stored under appropriate conditions or 
deliberately oxidized to also magnetic γ-Fe2O3. Despite all scientific efforts, control of 
particle size remains the weak point of the copreciitation method. Basic approaches for 
solving this problem contain the in situ stabilization of nanoparticles by polymers or 
carbohydrates during the precipitation process [54]. Uniform crystal growth can further be 
mediated by the use of special chelating agents [55]. A great advantage of the coprecipitation 
method with respect to biomedical applications is the complete lack of organic solvents. 
However, the prepared magnetic nanoparticles first have to be stabilized by protecting 
surfactant or polymer coatings, before they can be administered.  
Monodisperse iron oxide nanoparticles with high size control can be synthesized by the 
thermal decomposition of organometallic precursors like iron pentacarbonyl Fe(CO)5 or iron 
acetylacetonate Fe(acac)3. The reactions are carried out under the presence of surfactants in 
high-boiling organic solvents, and yield either pure metal or iron oxide nanoparticles, 
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depending on the valence of the precursor molecules. Initially formed metal nanoparticles can 
be easily converted to their oxides in a consecutive step. For example, Hyeon et al. prepared 
monodisperse γ-Fe2O3 nanocrystals by thermal decomposition of Fe(CO)5 in a mixture of 
octyl ether and oleic acid at 100 °C and subsequent oxidation of the intermediate by the 
addition of trimethylamine oxide [56]. In general, the dimensional and morphological 
properties of the nanoparticles are precisely tunable by controlling the reaction times and the 
temperature, as well as the concentrations and ratios of the employed reactants. In order to 
render the hydrophobic magnetic nanoparticles water-dispersible, polar molecules have to be 
introduced. This is managed, for example, by the exchange of surface ligands or the 
intercalation of amphiphilic molecules between stabilizer chains.  
Droplets inside water-in-oil microemulsions can serve as nanoreactors for the formation of 
iron oxide nanoparticles. The dimensions of the surfactant-stabilized water droplets are 
determined by the ratio of surfactant to water [57]. Consequently, the size of the nanoparticles 
can be controlled to a high extent. A popular pattern occurring in many synthesis protocols 
comprises the isovolumetric mixing of two analog microemulsions, one containing an iron 
salt solution, the other containing an alkaline precipitation agent [58]. The hydrophobic 
nanoparticles are recovered by acetone and ethanol treatment, and are readily dispersible in 
organic solvents. 
Besides the presented strategies, a multitude of methods are available for the fabrication of 
magnetic iron oxide nanoparticles, such as sol-gel reactions, hydrothermal synthesis and laser 
pyrolysis. Nevertheless, progress in this field is still ongoing. In microfluidic systems, 
reactants are compartmentalized in droplets and systemically fused by electrocoalescence. 
The generated nanoparticles exhibited very small sizes and narrow size distributions [59]. 




Table 3. Synthesis routes for the generation of magnetic (iron oxide) nanoparticles. 
Synthetic method Reaction 
temperature [°C] 
Solvent Shape control Yield 
coprecipitation 20 – 90 water − high / scalable 
thermal 
decomposition 
100 – 320 organic 
compound 
++ high / scalable 





220 water-ethanol ++ medium 
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OBJECTIVE OF THE STUDY  
 
The general objective of the present work was the development of a novel ferrofluid of high 
versatility for biomedical applications. Here, the main focus was on the suitability of  
designed formulations to operate as effective contrast agents in MRI studies. Our goal was to 
optimize these formulations in terms of functionality, selectivity and biocompatibility in order 
to overcome limitations of currently marketed MRI contrast agents. The overall process 
involved the synthesis and stabilization of ferrofluidic nanosuspensions based on magnetic γ-
Fe2O3 as well as the evaluation of their compliance with the technological requirements 
necessary for an effective in vivo application.  
Chapter 1 provides background information on the status quo of magnetic nanoparticles in 
various biomedical disciplines. Furthermore, general aspects of particular relevance for the 
better understanding of the topic are addressed, among these basic principles of 
magnetochemistry and magnetic resonance imaging, with the aim of imparting more 
transparency to the reader. 
In order to be qualified for biomedical applications, magnetic nanoparticles have to meet 
certain requirements. These include small size, monodispersity, high magnetization values, 
superparamagnetism and peculiar surface coating. The role of surfactant choice is not to be 
underestimated, since these agents provide stabiliztion, protection, functionalization and 
biocompatibility. Accordingly, it was our goal to generate nanoparticulate iron oxide 
formulations matching the specified features the best way possible. We assumed that 
appropriate selection and subsequent tuning of the synthesis route could maximize magnetic 
and relaxation properties of the nanocarriers. Furthermore, the implementation of a new class 
of surface stabilizers was supposed to confer combined compatibility and versatility to the 
magnetic carriers. In Chapter 2, respective experiments highlighting the influence of both 
synthesis procedure and stabilizer choice on the performance of magnetic nanoparticles are 
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described. Iron oxide nanoparticles were synthesized by an aqueous coprecipitation process, 
and thoroughly characterized with regard to their specifications. For the purpose of 
comparison, the magnetic cores were coated with either poly(ethylene imine), a standard 
polymer for the stabilization of iron oxide nanoparticles, or the grafted derivative 
poly(ethylene imine)-g-poly(ethylene glycol). It was hypothesized that the modification of 
nanoparticles with a surface stabilizer carrying PEG moieties would enhance the colloidal 
stability in protein-rich environments, and lead to a reduction in cytotoxicity. In addition, the 
relaxation parameters of the formulations were investigated in order to reveal the potential 
effectiveness in MRI contrast enhancement. As relaxation is a physical property brought 
about by the magnetic part of the compounds, we assumed it to be independent of the 
respective coating agent. Were the assumptions to be validated, the novel iron oxide 
formulation containing poly(ethylene imine)-g-poly(ethylene glycol) would possibly be able 
to compete with presently marketed MRI contrast agents. 
The investigations described in Chapter 3 move the focus to the cellular uptake of oppositely 
charged magnetic iron oxide nanoparticles. Based on the fact that the surface potentials of 
nanoparticular systems severely affect their cell internalization rate and mechanism, we 
anticipated a major difference in accumulation behavior and possibly cell-internal distribution 
in comparative uptake studies. Moreover, we attemptd to reveal implications of cellular 
localization for the relaxometric performance of magnetic nanoparticles. For that purpose, 
particle-loaded cells were subjected to different MRI sequences, in order to evaluate the 
contrast enhancement potential of the ferrofluids. The setups of the examined formulations 
differed in both the charge of the polymeric stabilizer and the applied synthesis route. 
Therefore, we assumed the cell uptake kinetics and r te to be a cooperative effect of several 
variables, but governed by surface charge. It was further hypothesized that accumulation of 
positively charged iron oxide nanoparticles would occur at a faster rate, and to a higher extent. 
In general, a pronounced uptake does not necessarily improve the signaling of a tissue in MRI 
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sequences, due to the detrimental effect of cell compartmentalization. However, we predicted 
this effect to be less pronounced for formulations with the potential for endosomal escape, 
such as the applied compounds of iron oxide and poly(ethylene imine). Such formulations 
were suggested to be highly valuable for applications such as stem cell tracking, which do 
require high cell loading levels with contrast agents and sufficient MRI signaling. 
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Magnetic iron oxide nanoparticles have found application as contrast agents for magnetic 
resonance imaging (MRI) and as switchable drug delivery vehicles. Their stabilization as 
colloidal carriers remains a challenge. The potential of poly(ethylene imine)-g-poly(ethylene 
glycol) (PEGPEI) as stabilizer for iron oxide (γ-Fe2O3) nanoparticles was studied in 
comparison to branched poly(ethylene imine) (PEI). Carrier systems consisting of γ-Fe2O3-
PEI and γ-Fe2O3-PEGPEI were prepared and characterized with regard to their 
physicochemical properties, including magnetic resonance relaxometry. Colloidal stability of 
the formulations was tested in several media, and cytotoxic effects in adenocarcinomic 
epithelial cells were investigated. 
Synthesized γ-Fe2O3 cores showed superparamagnetism and high degree of crystallinity. 
Diameters of polymer-coated nanoparticles γ-Fe2O3-PEI and γ-Fe2O3-PEGPEI were found to 
be 38.7 ± 1.0 nm and 40.4 ± 1.6 nm, respectively. No aggregation tendency was observable 
for γ-Fe2O3-PEGPEI over 12 hours, even in high ionic strength media. Furthermore, IC50 
values were significantly increased by more than 10-fold, when compared to γ-Fe2O3-PEI. 
Formulations exhibited r2 relaxivities of high numerical value, namely around 160 mM
-1 s-1.  
In summary, novel carrier systems composed of γ-Fe2O3-PEGPEI meet key quality 
requirements, rendering them promising for biomedical applications, e.g. as MRI contrast 
agents.  




Magnetic iron oxide nanoparticles (IONP) have met with increasing interest due to potential 
biomedical applications, amongst others in drug delivery [1, 2], magnetic resonance imaging 
(MRI) [3, 4] and hyperthermia of tumors [5]. Recently, he design of such carrier systems has 
moved towards multifunctionality based on drug loaded IONP [6, 7] and more selectivity by 
the attachment of targeting ligands [8]. In all cases, biocompatibility of IONP regarding 
immunogenicity and colloidal stability is of concern.  
In general, surface coatings are necessary which influence aggregation behavior, colloidal 
stability in blood, cytotoxicity, and furthermore play a significant role in pharmacokinetics 
and biodistribution in the body [9]. Stabilization strategies for magnetic iron oxide 
nanoparticles are mostly based on polymer coatings. Polymers investigated include 
crosslinked dextran, poly(lactic acid), poly(ethylene glycol), chitosan and polyvinyl alcohol 
[10]. Newer strategies concern amphiphilic polymers fo  phase transfer of IONP generated in 
organic solvents [11]. Also, cationic polymers such as poly(ethylene imine) (PEI) have been 
used to stabilize IONP by adsorptive coating on numerous occasions [12]. Such IONP have 
been investigated in the context of multifunctional c rriers, allowing imaging and nucleic acid 
delivery [13, 14],  but also for targeting and imaging purposes [15, 16].  
Problems associated with PEI coated IONP are their lack of colloidal stability and 
cytotoxicity associated with the polymer. It has been demonstrated that such IONP tend to 
aggregate in certain cell culture media and in the presence of serum proteins [17]. A potential 
strategy to overcome these problems could be the modification of PEI backbone with 
poly(ethylene glycol) (PEG), as PEG provides copolymers with increased stability, increased 
circulatory lives and lower toxicity [18]. Only scant information is available on IONP 
stabilized by copolymers of PEG and PEI [19]. 
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It was hypothesized that copolymers of the type poly(ethylene imine)-g-poly(ethylene glycol), 
PEGPEI could serve as coating agent for magnetic iron oxide nanoparticles, leading to 
enhanced colloidal stability and reduced cytotoxicity due to PEG shielding effects. To verify 
these assumptions, γ-Fe2O3 nanoparticles were coated with PEGPEI, using a straightforward 
manufacturing technique. These IONP were compared with PEI coated nanoparticles to 
evaluate the effect of PEG shielding. IONP were characterized with respect to 
physicochemical properties and composition. Moreover, colloidal stability and aggregation 




MATERIALS AND METHODS 
 
Materials 
Iron(II)chloride tetrahydrate and iron(III)chloride hexahydrate were purchased from Sigma 
Aldrich (Taufkirchen, Germany). Branched poly(ethylene imine) (PEI) with a molecular 
weight of 25,000 Da was a gift from BASF (Ludwigshafen, Germany). Block copolymers of 
the general composition PEI(25k)-g-PEG(20k)1, abbreviated as PEGPEI, were synthesized as 
previously described [20]. Synthesis procedures and dilution steps were carried out in ultra 
pure water (0.055 µS/cm, USF Seral, Seradest BETA 25 and Serapur DELTA UV/UF) unless 
otherwise stated. All other chemicals were obtained from commercial sources, and used as 
received without further purification. 
 
Preparation of γ-Fe2O3 nanoparticle cores 
Iron oxide nanoparticles were prepared by an aqueous c precipitation route adapted from the 
Massart process [21]. Briefly, concentrated ammonia solution (25 %) was slowly added to a 
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0.13 M slightly acidic solution of iron(III) chloride hexahydrate and iron(II)chloride 
tetrahydrate (molar ratio 2:1) until formation of a d rk black slurry occurred. After collection 
with a permanent magnet and triple washing with ultra pure water, particles were refluxed in a 
mixture of nitric acid and 0.34 M iron(III)nitrate nonahydrate at 90 °C for 30 minutes. The 
precipitate was collected by magnetic decantation and subsequently dispersed in water to 
yield a stable final suspension at pH 2. 
Functionalized nanoparticles were generated by mixing the iron oxide suspensions with PEI 
or PEGPEI polymer solutions for 30 minutes at a defined mass ratio [Fe] to [PEI] of 1:2. 
Unbound polymer was removed by dialyzing the suspenions in multiple cycles against a 500-
fold excess of ultra pure water, using Spectra/Por® membranes with MWCO 100,000 Da 
(Carl Roth, Karlsruhe, Germany).  
 
Characterization of  γ-Fe2O3 cores 
• Transmission electron microscopy 
Size and morphology of γ-Fe2O3 cores were investigated using transmission electron 
microscopy (TEM). Suspension droplets were placed onto carbon-coated copper grids S160-3 
(Plano, Wetzlar, Germany) and allowed to air dry. After insertion into the microscope JEM-
3010 (Jeol Germany, Eching, Germany), pictures were tak n at an acceleration voltage of 300 
kV. Core dimensions were calculated by averaging at le st 200 particle diameters using 
ImageJ software. 
 
• X-ray diffraction 
X-ray diffraction (XRD) patterns of naked iron oxide cores were recorded on a Panalytical 
X’Pert Pro powder diffractometer (Almelo, Netherlands) to characterize the crystallite type 
and structure of the material. For that purpose, particle suspensions were lyophilized and 
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desiccated thoroughly before being screened with the goniometer at 2θ angles from 20° to 80° 
at a stepwidth of 0.0131°. 
 
• Magnetization measurements 
The dried samples were further investigated with rega d to their expected superparamagnetic 
behavior. Small amounts of material were introduced into a Magnetic Property Measurement 
System MPMS® equipped with 5 T magnet (Quantum Design, San Diego, CA), using 
superconducting quantum interference device (SQUID) technology. Samples underwent a 
zero field-cooled field-cooled (zfc-fc) sweep from 5 to 350 K at a rate of 2 K/min and an 
external magnetic field strength of 50 and 500 Oe, respectively. 
 
Characterization of polymer-coated nanoparticles 
• Dynamic light scattering 
Hydrodynamic diameters of nanoparticles after polymer functionalization were assessed by 
dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern Instruments, Herrenberg, 
Germany). Measurements were performed at 25 °C after ppropriate dilution of the respective 
samples with ultra pure water to avoid multiscattering events. DTS v. 5.10-software was used 
to calculate both particle mean diameters from intensi y-weighted distributions (Z-Ave) and 
distribution widths displayed as the polydispersity index (PDI).  
 
• Thermal gravimetric analysis and FT-IR spectroscopy 
Investigations on the general and quantitative composition of polymer-coated iron oxide 
nanoparticles were carried out via thermal gravimetric analysis (TGA) and infrared 
spectroscopy (IR). In the course of the thermal anaysis, lyophilized samples of iron oxide, 
pure PEI or PEGPEI and core-shell compounds thereof w re tracked over a temperature range 
from 25 to 900 °C at a scan rate of 20 K/min under nitrogen atmosphere using a PerkinElmer 
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TGA 7 assembly (Rodgau, Germany). Samples of similar type were also subjected to infrared 
wavenumber scans between 4000 and 400 cm-1 on a Bruker FT-IR spectrometer with Alpha 
Platinum ATR sampling module (Bruker Optics, Ettlinge , Germany). 
 
Colloidal stability 
The stability of the polymer-coated formulations was tested in a dual set of experiments. 
Firstly, change of particle diffusivity in different relevant media was examined over a time 
scale of 30 minutes. Here, 10 µL of nanoparticle suspensions containing iron concentrations 
of 1 mg/mL were diluted 40-fold with one of the following agents: ultra pure water, sodium 
chloride 0.9  % (w/v), fetal calf serum (FCS) of different concentrations or Dulbecco’s 
Modified Eagle Medium (DMEM) high glucose supplemented with 10 % FCS and L-
glutamine. Trends of diffusion coefficients over the alf-hour period were read out by 
dynamic light scattering on a Zetasizer Nano ZS at 25 °C with settings analogous to the 
section stated above for size measurements.  
Secondly, the same formulations were analyzed at 37 °C for alterations in turbidity at 630 nm 
over 12 hours with an Ultrospec 3000 spectrophotomeer (Pharmacia Biotech, Vienna, 
Austria). Suspensions were mixed with the abovementioned solutions in a 1:40 ratio, and 
transmissions were recorded at given times. Samples were stored in a thermal block at 37 °C 
throughout the whole experiment, and redispersed prior to each measurement by vortexing. 
 
Cell culture and trypan blue exclusion assay 
Human lung adenocarcinoma cell line A549 was maintained in DMEM high glucose 
containing 10 % FCS and L-glutamine without the addition of antibiotics in a humidified 
atmosphere at 37 °C and 8.5 % CO2. For the experiment, cells were seeded onto 24-well 
plates at a density of 60,000 per well. After awaiting adherent growth, culture medium was 
exchanged with DMEM supplemented with 5 % FCS, in order to avoid interference with the 
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assay reagents. Immediately thereafter, the wells were incubated with increasing [Fe] 
concentrations of either iron oxide-PEI or iron oxide-PEGPEI for a period of 24 hours. For 
the purpose of comparison, treatment with pure PEI was performed, due to its well-known 
cytotoxic properties. Unmanipulated wells served as a control. After 24 hours, cells were 
washed twice with PBS to remove aggregated material, and 20 µL of 0.4 % trypan blue were 
added by pipet. Three minutes after addition of the dy , magnified pictures of the respective 
wells were taken on a camera-equipped microscope. Th  percentage of cell viability was 
determined by inspecting at least 200 cells for lack or presence of intracellular blue color, as 
dead cells soak up the dye due to loss of membrane integrity. 
 
MR relaxometry 
Magnetic resonance imaging studies were carried out on a 7 T Bruker ClinScan 70/30 USR 
(Bruker BioSpin, Rheinstetten, Germany). Concentration series of polymer-functionalized 
iron oxide nanoparticles were placed into microcentrifuge cups to avoid artifacts from 
surrounding air. For measurements of transverse T2 r laxation times, spin-echo multicontrast 
sequences were run at TR values of 2000 ms, varying spin echo times TE (10-150 ms with an 
increment of 10 ms), field of view 65x75 mm, matrix 112x128 and slice thickness 0.6 mm. 
Data quantification was achieved by evaluating DICOM images. T2 maps were generated 
from the overlay of successive spin-echo images, using a nonlinear monoexponential fitting of 
the signal intensity (SI) decay curve: SI (t) = S0 exp (-t/T2), where S0 is the signal magnitude at 
equilibrium and t the particular echo time. Relaxation times T2
 and their reciprocal values, 
relaxation rates R2 (=1/T2) could therefore be derived by analyzing regions of interest (ROI) 
within the created maps. 
Additionally, effective transverse relaxation times (T2* ) were calculated from T2* -weighted 
images taken with the following settings: gradient-cho multicontrast with TR 350 ms, 
multiple spin echo times TE (2-5 ms), field of view 58x78 mm, matrix 96x128, slice thickness 
 Chapter 2 51 
 
0.5 mm. T2*  values were obtained correspondingly by plotting the MRI signal intensities of 
the acquired maps versus echo times TE. 
 
Statistical analysis 
Measurements were carried out in triplicate and data are presented as mean ± S.D. unless 
otherwise noted. For statistical testing, one-way ANOVA in conjunction with Bonferroni‘s 




RESULTS AND DISCUSSION 
 
Particle synthesis 
Iron oxide nanoparticles prepared by the aqueous precipitation route suggested are generally 
of the maghemite (γ-Fe2O3) type, after mild oxidation of the intermediate modification 
magnetite (Fe3O4). Initial stabilization was conferred to the naked γ-Fe2O3 nanoparticles by 
electrostatic repulsion following peptization in acidi  environment. Ammonia solution was 
added dropwise to the reaction mixture to induce a short burst of nucleation and controlled 
growth of IONP. Both parameters have been described to be essential for size uniformity, 
according to the LaMer diagram [22]. Other factors determining particle size, such as type, 
molarity and ratio of iron salts, were kept constant throughout the whole manufacturing 
process. Mixing of iron oxide suspensions with polymer solutions yielded the formulations of 
interest, γ-Fe2O3-PEI and γ-Fe2O3-PEGPEI. The simplicity and lack of organic solvents 
generally render this coating procedure favorable for biological applications. 
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Physicochemical characterization 
• Size and morphology of γ-Fe2O3 cores 
The maghemite cores depicted on TEM pictures (Figure 1) were found to be irregularly 
shaped with an average diameter of 10.8 ± 3.0 nm, and arranged in clusters, because of their 
magnetic nature. Size values were obtained by averaging 200 core diameters, representing a 
number-weighted distribution pattern. Dynamic light scattering experiments showed 
considerably larger diameters, due to the inclusion of regions of agglomeration and the 
analysis in intensity-weighted mode (data not shown). Transmission electron micrographs 
revealed uniformly arranged planes inside the γ-Fe2O3 crystallite at very high magnifications. 
Relatively wide size distribution and poor control of the shape of IONP are drawbacks 
generally observed with the aqueous coprecipitation route [23]. Distribution width, however, 
is still in an acceptable range and the avoidance of organic solvents turns out to be beneficial 
for biomedical use. The high resolution images suggest an inverse spinel structure of the 
maghemite crystal lattice. 
 
 
Figure 1. Transmission electron micrographs on morphology of synthesized γ-Fe2O3 cores 
and crystallite structure at higher magnification (i set). 
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• Crystal modification of synthesized iron oxide  
Evidence of identity and crystal structure were furthe  verified by X-ray diffraction patterns. 
Intensity signals appeared at defined scattering angles 2θ with the most prominent ones at 
30.6°, 35.9°, 43.3°, 57.4° and 63.2° (Figure 2). The Bragg peaks could be assigned to specific 
diffraction planes inside the maghemite lattice: (2 2 0), (3 1 1), (4 0 0), (5 1 1) and (4 4 0). 
The assembly of the diffraction peaks is indicative of a cubic inverse spinel structure and 
conforms to maghemite/magnetite reference spectra due to the relative positions of signals 
[24].  
 
Figure 2. XRD pattern of prepared iron oxide (γ-Fe2O3) nanoparticles, indicative of inverse 
spinel structure. Signals are assignable to diffraction planes (2 2 0), (3 1 1), (4 0 0), (5 1 1) 
and (4 4 0) at 30.6°, 35.9°, 43.3°, 57.4° and 63.2°, respectively. 
 
In general, appearance of signals is regulated by the incident X-ray wavelength (Kα1: 1.5406 
nm, Kα2: 1.5444 nm). Distinguishability between the modificat ons γ-Fe2O3 and Fe3O4 is not 
possible due to the crystallographically isomorphous structures of both materials. Broadening 
of the peaks is caused by crystallite size and, to a lesser extent, lattice strain [25]. Crystallite 
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diameters were accessible by application of the Scherrer equation, which considers size 





B =  
where B is the half-value width of respective Bragg peaks, λ the applied X-ray wavelength, L 
the diameter, θ the Bragg angle and K the shape-dependent Scherrer constant (set to 0.9). The 
calculated mean diameters of 10.3 ± 1.2 nm supported findings from transmission electron 
microscopy. The slight discrepancies between both methods can be explained by the existence 
of thin amorphous layers on the surface of the iron oxide nanoparticles, and the already 
mentioned lattice strain. 
 
• Superparamagnetism 
Temperature-dependent magnetization measurements for naked iron oxide nanoparticles 
indicated the presence of a blocking temperature TB of 75 K, visible in the zero field-cooled 
section, at an external field strength of 50 Oe (Figure 3). Also, the rather broad distribution 
around the TB maximum was clearly noticeable. Moreover, the blocking temperature shifted 
to lower values at 500 Oe and vanished completely at higher magnetic field strengths (data 
not shown). The appearance of TB is an indicator for the superparamagnetic behavior of the 
types of iron oxide prepared. Nanoscale magnetic particles possess a so-called blocking 
temperature as thermal limit that divides blocked an  superparamagnetic state [27]. Above 
this value, thermal energy exceeds anisotropy energy and leads to randomization of magnetic 
moments much faster than the experimental time scale . As seen here, the thermal energy 
input upon heating of the samples disturbs the system , initially leading to unblocking and 
alignment of magnetic moments with the external magnetic field. Thereafter, iron oxide 
nanoparticles drift into the superparamagnetic state characterized by randomization of 
magnetic vectors and decrease of magnetization. It can thus be concluded that the IONP are 
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combining strong magnetic moments and paramagnetic behavior (superparamagnetism), 
which is of great importance for biomedical applications. 
 
Figure 3. Temperature-dependent magnetization of γ-Fe2O3 nanoparticles, as obtained from 
zero field-cooled – field-cooled (zfc-fc) sweep at an external field strength of 50 Oe. 




• Hydrodynamic diameters of polymer-coated nanoparticles 
All further physicochemical investigations were performed on the coated nanoparticle 
formulations after adsorptive layering with polymers. Particle sizes, as measured by dynamic 
light scattering, were found to be 38.7 ± 1.0 nm (γ-Fe2O3-PEI) and 40.4 ± 1.6 nm (γ-Fe2O3-
PEGPEI), suggesting an increase in radii of 13-15 nm u der the assumption that single iron 
oxide cores were layered with the respective polymers (Table 1). Polymer layer thickness is 
thus similar for both formulations, despite PEGPEI displaying almost double molecular 
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weight. The polydispersity indices (PDI) representing the widths of the fitted Gaussian 
distributions amounted to 0.212 ± 0.013 and 0.186 ± 0.018, respectively. 
 
 size (nm) r2 (mM
-1 s-1) r2* (mM
-1 s-1) 
γ-Fe2O3 10.8 ± 3.0 *   
γ-Fe2O3-PEI 38.7 ± 1.0 **  163.2 249.1 
γ-Fe2O3-PEGPEI 40.4 ± 1.6 **  155.7 231.7 
 
*   as measured by TEM 
**  as measured by DLS (n = 3) 
Table 1. Physicochemical parameters of magnetic iron oxide nanoparticles. 
 
As a result, these IONP had particle sizes smaller than those of the commercially available 
product Resovist® (60 nm) and may be designated as ultrasmall superparamagnetic iron 
oxide nanoparticles (USPIO). It has been shown earlier that poly(ethylene imine) can attach to 
very different surfaces within a broad pH range [28]. We assume that the binding mechanism 
of PEI onto maghemite is a combination of hydrogen bo ding and dipolar interactions. The 
slight difference in polymer layer thickness referred to, suggests in our opinion the orientation 
of PEG molecules along the nanoparticle surface, threby forming a protective shield in 
aqueous environment. Besides that, we observed an auto-regulation of the pH values after 
mixing iron oxide and polymer suspensions to numbers of 7.5 to 7.7, presumably evoked by 
the buffering capacity of the branched poly(ethylene imine) and its derivative PEGPEI. This 
enables an euhydric application of the formulation without further manipulations. So, despite 
its simplicity, this synthesis strategy permits thefabrication of small nanoparticulate carriers 
with relatively narrow size distributions at neutral pH. However, the colloidal stability of 
these adsorptive compounds remains to be addressed. 
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• Composition of polymer-coated nanoparticles   
In additional experiments, the relative composition of the hybrid particles, consisting of an 
inorganic iron oxide core and an organic polymer shell, was assessed by thermal analysis and 
IR spectrometry. Thermograms revealed a degradation onset for pure PEI at 370 °C and a 
biphasic degradation process for PEGPEI. The curves for the hybrid nanoparticles showed 
analogous patterns and remainder of the inorganic iron oxide cores at high temperatures 
(Figures 4a and b). Due to apparent minimum water residues in the samples, an absolute 
quantification of polymer contribution to the overall particle mass was difficult, but estimated 
to be 55 % in the case of PEI and 65 % for PEGPEI. The degradation temperature values 
obtained were in good accordance with results from earlier studies [29]. Furthermore, it 
became obvious that almost all polymer applied during the layering process of maghemite 
nanoparticles is bound to the surface (maximum mass fr ction PEI 59 % and PEGPEI 72 %). 
Only a small percentage got washed out during dialysis purification of the batches. 
 
   
Figure 4. Relative weight loss of hybrid nanoparticle systems (a) γ-Fe2O3-PEI and (b) γ-
Fe2O3-PEGPEI upon heating to 900 °C (TGA). Respective curves for naked γ-Fe2O3 cores 
and pure polymers were taken for comparison reasons. 
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Further evidence for the qualitative assembly of the hybrid nanoparticles was gained by 
infrared spectra, for clarity only data for the γ-Fe2O3-PEI type are shown. Vibration signals 
originating from the Fe-O bond were found at wavenumbers of 630, 585 and 440 cm-1 and 
coexisted for both pure maghemite and γ-Fe2O3-PEI nanoparticles (Figure 5). 
 
 
Figure 5. Infrared wavenumber scans for lyophilized γ-Fe2O3-PEI and its singular 
components. Spectra were arranged on top of each other for clarity. 
 
Moreover, characteristic bands for poly(ethylene imine), such as the N-H stretch at 3500-3300 
cm-1, were recorded and coincided with those of hybrid particles. Others reported that finite-
size effects in nanoparticulate maghemite cause splitting of the Fe-O ν1 band to values above 
570 cm-1 and shifting of the ν2 band (375 cm-1) to higher wavenumbers [30].  
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Colloidal stability in different media 
Diffusion coefficients of formulations γ-Fe2O3-PEI and γ-Fe2O3-PEGPEI in various media, as 
calculated from the DLS auto-correlation function, were recorded to identify alterations in 
overall particle size. The changes were most pronounced for γ-Fe2O3-PEI in supplemented 
cell medium DMEM with a 65 % decrease of diffusion coefficients after 30 minutes, while 
dispersion of both formulations in saline or fetal c f serum left the particle diffusivity rather 
unchanged, with a minor exception for very high protein levels in FCS 90 % (Figures 6a and 
b). Turbidity measurements over 12 h generally confirmed these findings, as the decay of 
transmission indicating aggregation of nanoparticles was found to be most distinct for γ-
Fe2O3-PEI in DMEM 10 % FCS (Figures 6c and d), also macroscopically observable by a 
complete loss of transparency.  
The results suggest that adsorption of serum components did not induce detrimental effects on 
stability of polymer-coated iron oxide nanoparticle systems, as seen by the constancy of 
relative diffusion coefficients. However, absolute sizes after protein adsorption were found to 
be slightly enhanced for the γ-Fe2O3-PEI type, hinting at facilitated and increased attachment 
of the protein fraction. When additionally introduced into a high ionic strength environment 
like DMEM, these carriers begin to precipitate massively, presumably due to shrinkage of the 
electrical double layers and loss of repulsive shielding between the particles. The improved 
performance of γ-Fe2O3-PEGPEI (in DMEM 10 % FCS) is assumed to be caused by an 
effective reduction in absolute protein adsorption levels, thus retaining individuality of the 
nanoparticles, and may be attributed in large part to the presence of surface PEG moieties. 
PEG coatings have been shown to prevent protein fouling and to provide steric hindrance 
suppressing aggregation [31]. As cell medium DMEM 10 % FCS has a similar ionic 
composition to simulated body fluid and equals human blood serum assembly, results are 
promising for a possible in vivo application of PEGPEI-modified nanoparticles. On the one 
hand, these particles can evade rapid sequestration in MPS organs due to their small size and 
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stability [32], on the other hand iron oxide pegylation offers possibly the beneficial effect of 
reduced protein opsonization in vivo. Through the synergistic combination of these 
mechanisms, the blood circulation half-lives of the carriers are supposed to be greatly 
enhanced, and hence the access to deeper compartments is facilitated [33]. 
 
  
   
Figure 6. Colloidal stability of nanoparticle formulations in NaCl 0.9 % (■), FCS 10 % (▲), 
FCS 90 % (▼) and DMEM supplemented with 10 % FCS (♦), as measured by changes of 
relative diffusion coefficients Drel and relative transmissions Trel over time. Initial values were 
set to 100 %. Course of Drel was monitored for (a) γ-Fe2O3-PEI and (b) γ-Fe2O3-PEGPEI 
nanoparticles (n = 3) in the different media. Graphs (c) and (d) show transmission data at 
630 nm for γ-Fe2O3-PEI and γ-Fe2O3-PEGPEI, respectively.    
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Cytotoxicity assessment 
A549 cell viability profiles after incubation with nanoparticulate [Fe] amounts of 0.1-100 
µg/mL were sigmoidally fitted and yielded IC50 values of 6.8 and 160 µg/mL [Fe] for γ-
Fe2O3-PEI and γ-Fe2O3-PEGPEI, respectively (data not shown). Due to the fact that 
cytotoxicity of hybrid iron oxide nanoparticles in the applied concentration range is caused to 
a major extent by their polymeric coatings [34], incubation concentrations were recalculated 
and standardized to polymer molarities of either PEI or PEGPEI, and viability curves were 
replotted for comparison purposes (Figure 7). For example, the incubation amount of 10 
µg/mL [Fe] equals 14.3 µg/mL of γ-Fe2O3 and, given the findings from TGA analysis, where 
hybrid γ-Fe2O3-PEI nanoparticles were found to contain 60 % of polymer, subsequently 21.5 
µg/mL or 0.86 µM of PEI. Thereafter, it could be seen clearly that poly(ethylene imine) 
layered on iron oxide particles exhibited cytotoxicity comparable to free PEI polymer, while 
PEGPEI created these effects only when applied at an lmost 20-fold amount. 
 
Figure 7. A549 cell viability, as observed by trypan blue exclusion assay after incubation with 
dilutions of PEI 25k (▲), γ-Fe2O3-PEI (■) and γ-Fe2O3-PEGPEI (●). Values are plotted 
against polymer fractions of each formulation. IC50 numbers were accessible by sigmoidal 
fitting of the curves. 
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Despite the implemented approximation, the informative value of the chosen display is in our 
opinion higher than for standard depictions plotting viability versus iron concentration. The 
highly destructive nature of poly(ethylene imine) originates from its strong cationic character, 
which is responsible for inducing defects into lipid bilayers [35]. Shielding of cytotoxicity has 
been reported to be brought about by covalent attachment of poly(ethylene glycol) to harmful 
polymers like PEI. However, the massive reduction in cytotoxicity seen here outscores 
findings for PEI(25k)-g-PEG(20k)1 polyplexes, where decrease in cell-detrimental effects 
upon pegylation was not that pronounced [36]. Also, m dification of PEI 25 kDa was shown 
to reduce cytotoxic and oxidative stress most effectiv ly at high degrees of PEGylation and 
low PEG chain lengths [37]. We explain the different behavior by the fact that PEG moieties 
on the surface of iron oxide nanoparticles are mainly directed towards the surrounding 
medium, thereby efficiently contributing to the shield ng of these systems, whereas 
polyplexes hide large parts thereof on the inside. Fetal calf serum concentration was reduced 
to 5 % prior to incubation experiments in order to minimize masking effects by proteins [38]. 
   
Potential of IONP as MRI contrast agent 
Relaxivities r2 and r2*  were accessible by measuring relaxation times for concentration series 
of the formulations γ-Fe2O3-PEI and γ-Fe2O3-PEGPEI via the general equation 
1 / T2 (*) = 1 / Tinit. + r2 (*) C 
where Tinit. represents the initial relaxation time, and T2 or T2*  are the relaxation times 
determined for [Fe] concentrations C. Experimental values for r2 at a magnetic field strength 
of 7 T ran up to 163.2 and 155.7 mM-1 s-1 for γ-Fe2O3-PEI and γ-Fe2O3-PEGPEI, respectively 
(Table 1). Gradient-echo T2*  images of linearly arranged concentration series of γ-Fe2O3-PEI 
suspensions revealed loss of signal decay with decreasing iron concentrations, visible by 
transient brightening of the respective microcentrifuge tubes (Figure 8). This phenomenon is 
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caused by the significant enhancement of transverse proton relaxation in the vicinity of areas 
containing magnetic iron oxide, thus leading to quick fading of MR signals.  
 
 
Figure 8. T2*-weighted image of γ-Fe2O3-PEI nanoparticle suspensions with [Fe] 
concentrations of 100, 50, 30, 20, 10, 5, 2, 1 and 0.1 µg/mL (top left to bottom right). 
 
As the coating thickness negatively affects the performance of magnetic nanoparticles, the 
slightly higher r2 and r2*  values for γ-Fe2O3-PEI particles can be attributed to their lower 
polymer fraction. However, the calculated r2 relaxivities are a measure for the efficiency of 
contrast agents and were found to be superior to most arketed products [39]. Taken together, 
the results prove the possibility of applying the formulations as MR contrast agents, e.g. for 
cell tracking, where accelerated uptake behavior mediat d by positive surface charges would 





An interesting alternative to current polymer candidates for coating of iron oxide 
nanoparticles was suggested to be poly(ethylene imine)-g-poly(ethylene glycol) (PEGPEI), 
representing in our opinion an advancement of pure oly(ethylene imine) in terms of colloidal 
stability and cytotoxicity, due to introduced PEG shielding moieties. We generated a novel 
magnetic carrier system based on the assembly of PEGPEI and iron oxide nanoparticles, 
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which meets the premium requirements for biomedical applications, amongst these small size, 
narrow size distribution and superparamagnetism. Despit  the simplicity of the synthesis 
procedure, γ-Fe2O3-PEGPEI particle systems displayed good colloidal stability over long-term 
range when suspended in critical cell media. Moreover, particle-associated toxicity was 
significantly reduced in contrast to correspondents γ-Fe2O3-PEI due to introduction of 
hydrophilic PEG groups to the polymer backbone. Relaxometric data underlined the general 
ability to enhance contrast in magnetic resonance imag ng. The findings confirm the stated 
assumptions of increased stability and reduced cytotoxicity after nanoparticle coating with 
PEGPEI. Given these results, iron oxide-PEGPEI nanop rticles possess great potential for 
biomedical applications. Especially the use of these carriers for cell tracking purposes is 
envisioned, where sufficient intracellular accumulation and concurrent absence of toxicity are 
needed. These effects are supposed to be balanced well for γ-Fe2O3-PEGPEI, but need to be 
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Chapter 3 Cell uptake behavior of oppositely charged  
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Sufficient accumulation of magnetic iron oxide nanoparticles inside certain tissues is 
beneficial for cellular magnetic resonance (MR) imaging. In our opinion, the extent of cell 
internalization in vitro can be controlled by several measures, including modulation of size, 
surface charge and colloidal stability.  
To investigate this, two series of maghemite (γ-Fe2O3) nanoparticles modified with polymers 
of opposite charge, in detail poly(ethylene imine) (PEI) and a polymaleic anhydride derivative 
(PMA), were synthesized and thoroughly characterized with respect to size, zeta potential, 
colloidal stability and magnetic properties. Furthemore, the uptake rate of both formulations 
into A549 carcinoma cells after fluorescent labeling of the carriers, as well as the resulting 
alteration in MR relaxation times were evaluated. Intracellular iron levels after 24 hour 
incubation with γ-Fe2O3-PEI particles were found to be almost 10-fold higher than those of 
their negatively charged counterparts. In addition, effective signal darkening in T2-weighted 
sequences was only achieved upon cellular incorporation of sufficient iron molarities, as it 
was seen for the γ-Fe2O3-PEI type.  
These findings underscore the cooperative effect of surface charge and colloidal stability on 
uptake, and highlight γ-Fe2O3-PEI suspensions as potential agents for cell tracking purposes, 





Magnetic iron oxide nanoparticles have moved into the focus of researchers due to their broad 
application range in biomedical disciplines, including drug delivery [1, 2], MR imaging [3, 4] 
and hyperthermia [5]. In recent years, much effort has been put into the development of iron 





oxide-based tracking agents allowing the non-invasive detection of specific cell types. Most 
investigations in this segment concern the surveillance of stem cell movement after insertion 
into the human body [6]. Further studies have shown the possibility of localizing transplanted 
graft tissues and their potential rejection in immunocompetent models, respectively, after iron 
oxide loading [7]. Limitations to these concepts can arise, for example, from insufficient 
cellular accumulation of magnetic carriers, leading to deficient usage as image probes [8]. 
Combined with the fact that MR signal enhancement, caused by conventional iron oxide 
nanoparticles, is still unsatisfactory compared to that obtained with other imaging modalities 
such as PET [9], the necessity for either high particle loadings or more efficient assemblies 
becomes obvious [10]. Several factors influence the cellular uptake of nanoscale objects, 
amongst these size, surface properties, cell type and endocytotic pathways [11]. Labeling 
characteristics of superparamagnetic iron oxide nanop rticles of different size have been 
reported to be superior for larger diameters [12]. Moreover, surface functionalization with 
charged moieties is known to affect the cellular uptake of polymeric nanoparticles [13], and 
these findings have also been transferred to inorgaic colloidal carriers [14]. In general, 
cationic magnetic nanoparticles were found to possess xcellent properties for tracking 
applications, as they enter cells with higher effectiv ness [15]. This has been proven for a 
variety of iron oxide formulations coated with polyelectrolytes of positive surface charge, 
such as poly(L-lysine) or dendritic guanidines [16]. However, thorough comparative analyses 
between oppositely charged magnetic nanoparticles ar  still missing. In order to accentuate 
the exclusive impact of surface charge on cellular accumulation of nanocarriers, in our 
opinion size effects have to be disabled by keeping article dimensions constant. Apart from 
the overall uptake rate of nanoparticulate objects, their respective pathway of internalization is 
manipulated by surface charge [17]. This is of crucial importance, as compartmentalization of 
iron oxide carriers, evoked by several internalization mechanisms, has been reported to 
negatively affect the eventual relaxivity behavior in MR imaging [18]. Therefore, the 





manipulation of non-phagocytic entering of nanocarriers into cells, which occurs mainly by 
adsorptive or receptor-mediated endocytosis and macropinocytosis [19], represents an 
interesting target. A parameter which is mostly excluded from in vitro internalization studies 
is agglomeration, although it contributes significantly to particle sedimentation, and 
subsequently to increased interaction with cell layers [20].  
On the basis of this knowledge, we hypothesized that t e cellular uptake rate of polymer-
coated magnetic nanoparticles can be favorably enhanced in vitro, by using cationic species 
with reduced colloidal stability. Resultant from tha , total iron loading levels are supposed to 
increase, thereby facilitating the detection by MR imaging. To support our assumptions, we 
developed two size-equivalent formulations of iron oxide modified with oppositely charged 
polymers by different synthesis routes, and studied their internalization kinetics and the 
localization inside carcinoma cells. In addition, the thus produced cells were fixed in tissue-




MATERIALS AND METHODS 
 
Chemicals 
Iron(II)chloride tetrahydrate and iron(III)chloride hexahydrate were purchased from Sigma 
Aldrich (Taufkirchen, Germany). Branched poly(ethylene imine) (PEI) with a molecular 
weight of 25,000 Da was a gift from BASF (Ludwigshafen, Germany). Fluorescein 
isothiocyanate (FITC) and Dy636 were from Sigma Aldrich (Taufkirchen, Germany) and 
Dyomics (Jena, Germany), respectively. All chemicals were obtained from commercial 
sources, and used as received without further purification. 
 





Synthesis γ-Fe2O3-PEI / particle system I 
Iron oxide nanoparticles of the maghemite type were prepared via aqueous coprecipitation, 
according to the Massart protocol [21]. Briefly, ammonia solution (2.6 mL, 25 % w/v)  was 
added to a slightly acidic solution of iron(III) chloride hexahydrate and iron(II)chloride 
tetrahydrate (100 mL, 0.13 M, molar ratio 2:1) under constant stirring, until persistence of a 
black slurry. Nanoparticles were collected by a permanent magnet and washed thrice with 
ultra pure water, then refluxed in a mixture of nitric acid (2 N HNO3) and iron(III)nitrate 
nonahydrate (0.34 M) at 90 °C for 30 minutes. The pr ci itate was gathered by magnetic 
decantation, and subsequently dispersed in water to yield a stable maghemite suspension. 
Following that, dispersions were reacted with poly(ethylene imine) (PEI) solution at a defined 
mass ratio of [Fe] to [PEI] of 1:2 under vigorous shaking for 30 minutes. Unbound polymer 
was removed by extensive dialysis across Spectra/Por® membranes with MWCO 100,000 Da 
(Carl Roth, Karlsruhe, Germany). 
 
Synthesis γ-Fe2O3-PMA / particle system II 
Nanocrystals of the γ-Fe2O3 type were prepared according to the method described by Hyeon 
and coworkers [22]. Briefly, 10 mL of octyl ether and 1.28 g of oleic acid were mixed and 
degassed in a 50 mL flask at 60 °C for 20 minutes. Then, 0.29 mL of Fe(CO)5 were added at 
100 °C and the solution was heated up slowly to refluxing temperature (~ 300 °C) for 1 h. The 
solution was cooled down to room temperature, and 0.34 g of (CH3)3NO were added. The 
mixture was heated up and maintained at 130 °C for 2 h, then refluxed at 300 °C for another  
2 h. After stopping the reaction, particles were prcipitated by addition of anhydrous toluene 
and methanol, followed by alternating washing steps with toluene and methanol, and final 
redispersion of particles in toluene (hydrophobic nanoparticles). 
Amphiphilic poly(maleic anhydride) derivative (PMA) was synthesized and used for the 
transfer of hydrophobic nanoparticles to aqueous solution, according to a previously 





published protocol [23]. Briefly, 500 µL of amphiphlic polymer solution (0.5 M) were mixed 
with 2 mL of hydrophobic nanoparticles (0.48 µM). After mixing, the solvent was slowly 
evaporated under reduced pressure, until the sample was completely dried. The remaining 
solid film was redissolved in SBB (sodium borate, 50 mM, pH 12) under vigorous stirring to 
yield clear nanosuspensions of γ-Fe2O3-PMA particles. 
 
Physicochemical characterization 
Size and morphology of the synthesized iron oxide cores were investigated on a JEM-3010 
transmission electron microscope (Jeol Germany, Eching, Germany) at an acceleration 
voltage of 300 kV. Maghemite suspension droplets were placed onto carbon-coated copper 
grids S160-3 (Plano, Wetzlar, Germany) and allowed to ry. Core dimensions were calculated 
by averaging at least 200 diameters registered by ImageJ software. 
Hydrodynamic diameters and zeta potentials of nanoprticles after polymer functionalization 
were assessed by dynamic light scattering (DLS) and l ser Doppler anemometry (LDA), using 
a Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany). DLS measurements were 
performed at 25 °C after appropriate dilution of the respective samples with ultra pure water, 
to avoid multiscattering events. As to LDA analysis, samples were dispersed in sodium 
chloride (10 mM) in order to maintain a constant ionic strength. 
For magnetization studies, small amounts of lyophilized material (~ 1.5 mg) were placed into 
a Magnetic Property Measurement System MPMS® equipped with 5 T magnet (Quantum 
Design, San Diego, CA) using superconducting quantum interference device (SQUID) 
technology. Magnetization values of the samples were surveyed during a field-dependent 
sweep from −55,000 to 55,000 Oe at room temperature. 
 






ICP-OES (inductively coupled plasma - optical emission spectroscopy) technology was 
applied for [Fe] quantification. After lysis of iron oxide nanoparticle systems with nitric acid 
(65 % w/v), absorbance of samples was measured at three different wavelengths (238.2 nm, 
239.6 nm, 259.9 nm) on an Optima 2000 DV (PerkinElmer, Rodgau, Germany). Amounts of 
iron were calculated by standardization to internal st ndard yttrium(III)chloride. 
 
Labeling of particle systems 
For fluorescent tagging of particle system I, green dye FITC was conjugated to PEI as 
previously described [24]. The labeled polymer was ttached to naked maghemite 
nanoparticles analogous to the synthesis protocol, thereby yielding γ-Fe2O3-PEI-FITC 
carriers.  
Particle system II was tagged with red marker Dy636 in a two-step process. First, 1 mg of 
amine-containing dye was dissolved in 0.4 mL of methanol and reacted with 0.5 mL of PMA 
solution in CHCl3. The solvent mixture was exchanged to anhydrous chloroform, and the final 
polymer concentration was set to 10 mM. Then, 2.5 mL of Dy636 modified amphiphilic 
polymer were mixed with 2 mL of hydrophobic γ-Fe2O3 nanoparticles (0.48 µM). The 
mixture was treated analogously to abovementioned unlabeled particles to yield stable           
γ-Fe2O3-PMA-Dy636 nanosuspensions. 
 
Cell culture and uptake studies 
Human lung adenocarcinoma cell line A549 was maintained in DMEM high glucose 
containing 10 % FCS and L-glutamine without the addition of antibiotics in a humidified 
atmosphere at 37 °C and 8.5 % CO2. 
For experiments on uptake kinetics, cells were seeded onto 24-well plates at a density of 
60,000 per well. After awaiting adherent growth, culture medium was exchanged with 





DMEM supplemented with 5 % FCS, in order to avoid interference with the assay reagents. 
Immediately after this, the wells were incubated with either particle system I or particle 
system II at fixed iron concentrations (1 µg mL-1). For the purpose of comparison, blank cells 
and wells treated with unlabeled particle species wre included. Following definite incubation 
times (5 min, 15 min, 30 min, 60 min, 2 h, 4 h, 8 h, 24 h), cells were washed twice with PBS, 
trypsinized and fixed in a 1:1 mixture of FACSFlowTM and paraformaldehyde (4 % w/v). Cell 
dispersions prepared in this way were analyzed withrespect to their fluorescent intensity via 
flow cytometry (FACS), using a FACSCanto II (BD Biosciences, San Jose, CA). Signals 
from a total of 10,000 cells were recorded on channels 488 nm and 630 nm, respectively.  
 
Agarose phantom relaxometry 
A549 cells were plated at a density of 100,000 per w ll, and incubated with iron oxide 
suspensions of different types (γ-Fe2O3-PEI and γ-Fe2O3-PMA) and concentrations (1, 10, 30 
and 50 µg mL-1) for 24 hours. After PBS washing and trypsinization, cell numbers were 
counted by means of a Neubauer chamber. Quantification of cell-internalized iron was 
realized by ICP-OES after cell lysis in concentrated nitric acid (600 µL) for 4 hours. 
Phantoms for MR relaxometry were produced by dispersing 105 doped A549 cells in agarose 
(1 % w/v). Magnetic resonance (MR) imaging studies concerning the T2 and T2*  relaxation 
times of the respective phantoms were carried out on a 7 T Bruker ClinScan 70/30 USR 
(Bruker BioSpin, Rheinstetten, Germany). For measurements of transverse T2 relaxation 
times, spin-echo multicontrast sequences were run at TR values of 2000 ms, varying spin echo 
times TE (10-120 ms with an increment of 10 ms), field of view 75x75 mm, matrix 128x128 
and slice thickness 0.6 mm. Data quantification wasachieved by evaluating the such created 
DICOM images. Relaxation times T2
 could be derived by analyzing regions of interest (ROI) 
within T2 maps generated by the overlay of successive spin-echo images, using a 
monoexponential fitting of the signal intensity (SI) decay curve: SI (t) = S0 exp (-t/T2), where 





S0 is the signal magnitude at equilibrium and t the particular echo time. Effective transverse 
relaxation times (T2* ) were calculated from T2* -weighted images taken with the following 
settings: gradient-echo multicontrast with TR 350 ms, multiple spin echo times TE (3-32 ms), 
field of view 89x89 mm, matrix 128x128, slice thickness 0.5 mm. T2*  values were obtained 






The different synthesis strategies for formation of γ-Fe2O3 nanoparticles clearly had an impact 
on the resulting morphology (Figure 1). While inorganic cores generated by aqueous 
coprecipitation (particle system I) were found to be irregularly shaped, those coming from 
thermal decomposition of organometallic precursor mlecules were of perfect spherical shape 
(particle system II). 
 
        
Figure 1. Transmission electron micrographs depicting the morphology of γ-Fe2O3 
nanoparticles after synthesis by (a) aqueous precipitat on route and (b) thermal 
decomposition of organometallic precursors. 





Analysis of Feret diameters on TEM micrographs furthe  revealed mean diameters of 10.4 ± 
2.4 nm and 10.8 ± 0.12 nm for the two setups, respectively. Adsorptive attachment of 
poly(ethylene imine) completed particle system I (γ-Fe2O3-PEI), whereas intercalation of 
polymer strands between surfactant alkyl chains formed the final step in producing particle 
system II (γ-Fe2O3-PMA). Hydrodynamic diameters for the two polymer-modified 
formulations, as measured by dynamic light scattering, amounted to 38.8 ± 0.3 nm and 37.4 ±
0.8 nm. Both types of nanoparticle suspensions exhibited unimodal size distributions and zeta 
potentials of comparable absolute value, in numbers 16.8 ± 1.1 mV for γ-Fe2O3-PEI and –18.7 
± 0.6 mV for γ-Fe2O3-PMA (Table 1). 
 
Table 1. Physicochemical parameters of magnetic iron oxide nanoparticles.  
 
The impact of preparation technology on magnetic features of the samples was investigated 
by monitoring field-dependent magnetization data on a SQUID system (Figure 2). All 
recorded curves showed lack of remanence and typical sigmoidal characteristics. Saturation 
magnetizations, i.e. the states of maximum alignment of magnetic spins at strong external 
fields, were derived by tangential fitting of the curve maxima. Numerical values decreased 












γ-Fe2O3-PEI 38.8 ± 0.3 0.144 ± 0.019 16.8 ± 1.1 23.7 
γ-Fe2O3-PMA 37.4 ± 0.8 0.321 ± 0.025 -18.7 ± 0.6 16.4 





For counterparts γ-Fe2O3-PMA, values were reduced from 27.7 emu g-1 for hydrophobic γ-




Figure 2. Field-dependent magnetization curves of bare (γ-Fe2O3 from aqueous synthesis) 
and polymer-coated (γ-Fe2O3-PEI and γ-Fe2O3-PMA) iron oxide nanoparticles at 298 K. 
 
When incubating A549 cells with fluorophore-bearing particle systems I and II, different 
qualitative uptake patterns were observed for the two species. Positively charged γ-Fe2O3-
PEI-FITC nanoparticles were internalized in a steady manner over the examined period of 24 
hours, with the predominant uptake taking place within the first two hours after incubation 
(Figures 3a and b). Single-peaked mean fluorescence intensity signals indicated, that there 
were no cell population subsets with lower degrees of particle incorporation. In contrast to 
that, negatively charged particles γ-Fe2O3-PMA-Dy636 were seen to accumulate in cells only 
to a small extent within two hours. The major fraction of these carriers was incorporated 
between time points 4 and 24 hours, mostly after 8 hours. Interestingly, γ-Fe2O3-PMA-Dy636 
were incorporated faster by the cells in the presence of γ-Fe2O3-PEI-FITC. 







Figure 3. Cellular uptake kinetics of nanoparticle formulations γ-Fe2O3-PEI-FITC (a) and γ-
Fe2O3-PMA-Dy636 (b). Cells were incubated with distinct amounts of the respective particle 
systems (1 µg [Fe]) for time periods of 15 min, 60 min, 4 h and 24 h. Fluorescence intensities 
were recorded by means of flow cytometry for a total f 10,000 events on channels FITC 
(excitation 488 nm) and APC-A (630 nm). (Dot plot used for cell gating is shown on the upper 
chart.) 





Intensity signals were measured via confocal laser scanning microscopy (Figure 4) and 
FACS, but as measurements were performed on different FACS channels and labeling 
efficiencies of the two particle systems were not hmogenous, absolute comparability 
between γ-Fe2O3-PEI-FITC and γ-Fe2O3-PMA-Dy636 was not given before quantification of 
cell iron via ICP-OES, following analogous incubation regimes. 
 
 
Figure 4. Investigations on cellular uptake kinetics of nanoparticle formulations γ-Fe2O3-
PMA-Dy636 (top), γ-Fe2O3-PEI-FITC (middle), and a co-incubation mixture of both (bottom) 
by means of laser scanning confocal imaging. A549 cells were incubated with the 
corresponding nanoparticles, and the cell membranes as well as the nucleus were stained 
with wheat germ agglutinin – alexa 594 or DAPI, resp ctively.  
 





When cells were exposed to particle system I at an initial dose of one microgram [Fe], about 
12 % of this amount were found to be internalized after 24 hours. Consistent with the findings 
from flow cytometry, the uptake of this species increased constantly over time. Unlike that, 
particle system II invaded A549 cells to a significantly lower extent of 1.5 %. Data points 
after 15 and 60 minutes were indistinguishable from background, and the most pronounced 
rise in intracellular iron mass appeared after four hours. Nevertheless, the results from ICP-
OES correlated well with MFI values from flow cytometry, as indicated by the calculated 
coefficients of determination for each of the formulations (R2 = 0.993 and R2 = 0.990 for γ-
Fe2O3-PEI-FITC and γ-Fe2O3-PMA-Dy636, respectively) (Figure 5).  
 
 
Figure 5. Quantification of absolute intracellular iron contets after 24 h incubation of A549 
cells with formulations γ-Fe2O3-PEI-FITC and γ-Fe2O3-PMA-Dy636 (red bars). Correlation 
of these data with mean fluorescence intensity values gained after identical cell treatment 
(green bars) were performed for comparison of methods ICP-OES and flow cytometry. 





Relaxation parameters of manufactured agarose phantoms containing doped cells were  
dependent on the effective amounts of iron per cell. As expected, A549 incubation with high 
iron molarities caused non-proportional enhancement of intracellular accumulation. For 
particle system I, maximum incubation with a total of 50 µg [Fe], for instance, led to 
intracellular iron levels of 6.9 pg per cell, and sub equent relaxation rates R2*  of 23.0 s
-1. An 
identical application scheme of particle system II resulted in values of 1.4 pg per cell and 8.2 
s-1.  
 
Figure 6. Relaxation rates R2* of agarose phantoms containing 10
5 cells doped with 
maghemite nanoparticles. Data points represent intracellular iron levels after incubation with 
increasing amounts of γ-Fe2O3-PEI (■) and γ-Fe2O3-PMA (□), respectively (1, 10, 30 and 50 
µg [Fe]). 
 
Despite the discrepancy in absolute R2*  numbers, the efficiency of both iron oxide 
nanoparticle setups in reducing transverse relaxation times, often denoted as relaxivity r2* , 
turned out to be equivalent, as derived from comparison of the slopes of the best-fit lines 
(Figure 6). 







In order to study the role of surface chemistry in modulation of cellular uptake and 
relaxometric performance, maghemite nanoparticles prepared from alternative synthesis 
routes were modified with positively charged poly(ethylene imine) and negatively charged 
PMA, respectively. Much effort had to be put into the establishment of manufacturing 
protocols for the two different carrier systems, due to the fact that equal dimensions of the 
fabricated iron oxide cores and the entire polymer-coated nanoparticles were required for 
comparison purposes. We created particle systems of opposite surface potential with the 
above specifications, namely γ-Fe2O3-PEI and γ-Fe2O3-PMA. The discrimination between 
both particle setups, apart from the measured zeta potentials, was possible by investigating the 
regularity in morphology of precipitated maghemite crystals. Relatively wide size distribution 
and non-controllable shape of particles are the two main drawback criteria suffered from the 
aqueous coprecipitation route [25]. However, keeping i  mind the scope of biomedical 
application, these slightly negative features are compensated by the easy handling and the 
absence of organic solvents. Additionally, synthesis trategy seems to affect magnetic 
properties of the fabricated iron oxide nanoparticles. It is well-known that magnetization of 
inorganic colloids is determined primarily by their c ystal diameter. As maghemite core 
dimensions were found to be almost identical, we assume that crystallinity represents the 
essential parameter for variation in overall saturation magnetizations (Msat) of the two particle 
systems. Another explanation for the differing Msat values might be the existence of a 
magnetically dead layer on the maghemite surface, which does not contribute to the collective 
magnetic moment of γ-Fe2O3 nanoparticles. The general reduction in magnetization, with 
respect to bulk maghemite [26], can be attributed to several mechanisms, such as spin canting 
or spin-glass-like behavior of the surface spins, both of them being effects which become 
more and more important with decreasing particle siz . Polymer shielding of the naked iron 





oxide cores induced further lowering of gram-standardized saturation magnetizations, which 
appears logical as the organic material does not add to the magnetic properties of the 
respective particle systems. Moreover, organic ligands used to stabilize magnetic 
nanoparticles lead to quenching of surface magnetic moments [27]. Displayed sigmoidal 
curves are indicative of superparamagnetism of both γ-Fe2O3-PEI and γ-Fe2O3-PMA. This 
feature is not only beneficial due to the availability of giant magnetic moments, but also due 
to the reduction in agglomeration tendency, which is attributable to complete paramagnet-like 
loss of magnetization at zero external field. 
Several models have been stated for the internalization of differently charged iron oxide 
nanoparticles [28]. However, no efforts have been made so far to directly compare particle 
systems of equal dimensions and opposite charge with respect to their cellular uptake rate. 
Consequently, our approach consisted in eliminating size as a key factor for nanoparticle 
uptake by keeping the diameters of the two formulations constant. We hypothesized that, 
under these circumstances, the invasion into cells was only dependent on the surface potential 
and the colloidal stability of incubated carriers. The steady, but nonlinear uptake pattern of 
positively charged γ-Fe2O3-PEI carriers suggests the involvement of a saturable, receptor-
mediated mechanism of cell intrusion. Other internalization routes proposed for magnetic iron 
oxide nanoparticles are macropinocytosis and adsorptive endocytosis [29]. The low extent of 
uptake for γ-Fe2O3-PMA particles after 24 hours was most striking. Electrostatic interactions 
with the negatively charged cell membrane certainly favor fast attachment and subsequent 
ingestion of cationic species γ-Fe2O3-PEI, but can hardly explain the extreme discrepancies 
observed. Thus, our opinion is that colloidal stability of the respective nanoparticle systems  
plays a cooperative role not to be underestimated in uptake kinetics. In the course of the 
experiments, primary agglomerates dispersed in the sup rnatant tend to sediment more rapidly 
onto the ground cell layer, according to Stokes’ Law. The aggregation tendency, as indicated 
by findings from gel electrophoresis measurements, is ignificantly increased for positively 





charged γ-Fe2O3-PEI particles. Consequently, the particle-cell contact area is largely 
enhanced, leading to higher total internalization rates. Although the phenomenon of colloidal 
instability drastically limits the application of such carrier systems, their rapid enrichment in 
certain tissues in vitro outbalances this drawback. Sufficient and fast loading of certain cell 
types is, for example, desired for tracking purposes via magnetic resonance imaging [30]. The 
reason for this is the concentration-dependent enhancement of transverse proton relaxation in 
the vicinity of areas containing magnetic iron oxide, thus leading to quick fading of MR 
signals and gain of contrast in T2-weighted images [31]. Based on that knowledge, particle 
system γ-Fe2O3-PEI should perform superior to its anionic counterpart, when being used for 
cell tracking tasks. In order to corroborate that hypothesis, agarose phantoms containing iron-
labeled cancer cells were subjected to MR measurement sequences. Phantom matrices act as 
versatile human tissue equivalents, as alteration of their basic composition allows for the 
imitation of specific intracorporal regions, and appendant relaxation properties [32]. Most 
effective signal darkening in T2-weighted maps, denoted as high absolute relaxation rate 
values R2* , was observed for cell dispersions carrying large amounts of γ-Fe2O3-PEI. 
However, the effects were not as pronounced as for freely dispersed nanoparticles. We 
explain this behavior by the intracellular confinement of magnetic iron oxide carriers, which 
has a strong impact on the detected proton relaxation times [33]. Coming back to the 
magnetization properties of the tested formulations, we predicted higher molar relaxivities for 
the system γ-Fe2O3-PEI, due to enhanced magnetic interactions with surrounding proton 
spins. Surprisingly, the efficiencies of both tested formulations were found to be in the same 
range. The relativization of this parameter is, in our opinion, a consequence of the clustering 
of particles brought about by both colloidal instability and organelle compartmentalization. 
Altogether, the results point out that magnetic iron oxide nanoparticles of the γ-Fe2O3-PEI 
type are promising for cell labeling and subsequent tracking purposes.  
 







We successfully synthesized iron oxide nanoparticle systems of opposite charge, and 
evaluated them with respect to physicochemical properties, cell uptake patterns and 
relaxometric performance. Surface modification of the generated carriers was found to be the 
key factor governing the internalization into cells. Positively charged γ-Fe2O3-PEI particles 
accumulated rather rapidly, due to a synergistic dual mechanism of attractive forces to the cell 
membrane on the one hand, and deficient colloidal stability on the other hand. Although slight 
agglomeration tendency of nano-sized particles restrict  their applicability in vivo, this 
problem is of minor importance for in vitro purposes. Cells incubated with γ-Fe2O3-PEI 
compounds revealed high numeric iron loadings, and subsequently effective signal darkening 
in MR sequences. These findings suggest γ-Fe2O3-PEI suspensions as promising agents for 
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This thesis presents the development of novel formulations on the basis of magnetic iron 
oxide nanoparticles. Optimization of the synthesis route resulted in the development of 
particles meeting general requirements for eventual app ications. Furthermore, the selection of 
appropriate stabilizing agents imparted the nanoparticles with beneficial features, making an 
in vivo application possible. In doing so, the formulations seem to be especially promising for 
the application as contrast agents in magnetic resonance imaging. 
Chapter 1 gives a brief insight into current research in the field of magnetic nanoparticles. 
While the originally promoted idea of dragging nanoparticles to the site of action by a 
massive external field is becoming less important, the use of magnetic carriers as single and 
multifunctional imaging agents is gaining in importance. 
Chapter 2 describes the synthesis of magnetic iron oxide nanop rticles with optimal 
properties for MRI contrast enhancement and the comparative assessment of polymeric 
macromolecules as stabilizers for such nanoparticles. It was revealed that particles covered by 
poly(ethylene imine)-g-poly(ethylene glycol) performed better than their poly(ethylene imine) 
counterparts, in terms of stability and cytotoxicity. The systems containing the former 
polymer showed pronounced colloidal stability even in protein-rich cell media. In addition, 
cytotoxicity was reduced by more than an order of magnitude. In this respect, the assumptions 
made in the run-up to the studies have found confirmation. Indeed, the introduction of 
hydrophilic poly(ethylene glycol) moieties to the polymer backbone positively manipulated 
the above properties. In addition, the physicochemical properties of the generated iron oxide 
nanoparticles were found to be excellent, despite the simplicity of the synthesis procedure. 
The iron oxide cores displayed high crystallinity, high saturation magnetization and 
superparamagnetic features. The polymer-coated nanoparticles were narrowly distributed 
around an average diameter of 40 nm and showed relaxation parameters comparable to 
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presently marketed products. Given these results, the established magnetic ferrofluids appear 
to be interesting for an intracorporal application as an MRI contrast agent. 
The assumption that the configuration of magnetic nanoparticles affects cell uptake 
(mechanisms) and localization, and subsequently celular MRI signaling, provided a basis for 
further studies. Chapter 3 includes the evaluation of oppositely charged iron xide 
nanoparticle systems with regard to physicochemical properties, cell interaction and cell-
constrained relaxometry. The findings of this section confirm that surface potential is the key 
factor controlling cell internalization of magnetic iron oxide nanoparticles. Particles with a 
positive zeta potential were taken up to an almost tenfold extent after 24 hours, and with faster 
kinetics than the negatively charged counterparts. Basically, these results confirm the 
preliminary assumptions that electrostatic attractive forces between the cell membrane and the 
nanoparticles favor an enhanced internalization of p sitive carriers. However, the clear 
discrepancy in overall uptake led to the conclusion that synergistic effects, such as colloidal 
stability, also influence the rate of particle accumulation in cells. Both systems were found to 
be compartmentalized in endosomes after their uptake into cells by a correspondent 
endocytotic pathway. This cellular confinement caused the relaxation parameters to change in 
comparison to freely dispersed nanosuspensions, in such a way that the signal contrast in T2-
weighted MRI sequences degraded. Nevertheless, phantoms of cells incubated with positively 
charged nanoparticles still revealed effective signal darkening in these MRI sequences. The 
results suggest the suspensions examined as promising agents for cell tracking purposes, as 
here high iron uptake in combination with pronounced r laxivity is required. 





The development of a novel ferrofluid based on iron oxide and poly(ethylene imine)-g-
poly(ethylene glycol) has been successfully accomplished. Moreover, the general potential of 
this formulation for biomedical applications has been demonstrated. The platform created 
facilitates the continuation of research in various directions. Among the many possibilities 
available, formulation testing in vivo seems to be the most reasonable option. In this context, 
biodistribution patterns after intravenous administration could be recorded, in order to identify 
accumulation in tissues other than the liver. However, in case the magnetic nanoparticles are 
rapidly transported in large part to the liver, they can still be tested for the detection of focal 
lesions. Most MRI contrast agents marketed are indicated for this kind of disorder, due to 
their missing tissue selectivity. Nevertheless, the future goal must be to achieve sufficient 
degrees of tumor selectivity. One approach, which has been discussed for several years, is the 
attachment of small molecules or other targeting moieties to the formulated nanoparticles. For 
the abovementioned particles, such a functionalization would be relatively easy, as the linker 
molecule in the form of poly(ethylene glycol) is intr sically present. Depending on the 
selection of the targeting moiety, artificial tumors implanted into the flanks of mice could 
accumulate sufficient amounts of nanoparticles, andthus be imaged in a high-contrast 
manner. Concerning cell tracking purposes, it would be interesting to determine the maximum 
loading levels of different cell types with the ferrofluidic nanoparticles. Here, an upper limit is 
naturally set by cytotoxic side effects.  
Besides the application in the domain of magnetic resonance imaging, ferrofluids can also be 
used for hyperthermia treatments. After loading cells with magnetic nanoparticles, it might be 
possible to selectively destroy the cells by an RF pulse. 





In der vorliegenden Arbeit wird die erfolgreiche Entwicklung neuer Formulierungen auf der 
Basis magnetischer Eisenoxidnanopartikel vorgestellt. Durch Optimierung der Syntheseroute 
gelang es, Partikel zu entwickeln, die die generelln Anforderungen für eine anschließende 
Anwendung erfüllen. Die hergestellten Nanopartikel onnten zudem durch die Auswahl 
geeigneter Stabilisatoren derart ausgestattet werden, dass eine Applikation i  vivo möglich ist. 
Dabei scheinen die Formulierungen besonders aussicht reich für die Verwendung als 
Kontrastmittel im Bereich der Magnetresonanztomographie (MRT) zu sein. 
Kapitel 1 gibt einen kurzen Einblick in den derzeitigen Stand der Forschung auf dem Gebiet 
magnetischer Nanopartikel. Während die ursprünglich propagierte Idee, magnetische 
Nanopartikel durch starke Magnetfelder an einen Wirkort zu bringen, immer mehr an 
Bedeutung verliert, steigt ihr Stellenwert als uni- oder multifunktionales Kontrastmittel für die 
MRT stetig. 
Kapitel 2 beschreibt die Synthese magnetischer Eisenoxidnanopartikel mit optimalen 
Eigenschaften für die Kontrastgebung sowie die vergleichende Bewertung verschiedener 
polymerer Makromoleküle zur Stabilisierung dieser Pa tikel. Es konnte gezeigt werden, dass 
die Umhüllung der Kerne mit Polyethylenimin-g-Polyethylenglykol (im Gegensatz zu 
Polyethylenimin) zu Partikeln führte, die bessere Eigenschaften hinsichtlich Stabilität und 
Zytotoxizität aufwiesen. Dabei zeigten Systeme mit erstgenanntem Polymer sogar in 
proteinreichen Zellmedien ausgeprägte kolloidale Stabili ät. Außerdem konnte für dieses 
System eine Verminderung der Zytotoxizität um mehr als den Faktor zehn festgestellt werden. 
Insofern wurden die Annahmen aus dem Vorfeld der Studie bestätigt. Die Anbringung von 
Polyethylenglykol-Resten ans Polymerrückgrat führte in der Tat zur Veränderung der 
genannten Eigenschaften – Stabilität und Zytotoxizität – in die vorausgesagte Richtung. Des 
Weiteren ergab sich, dass die physikochemischen Eigenschaften der Eisenoxidnanopartikel 
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trotz der Einfachheit der Synthesemethode herausragend waren: die Eisenoxidkerne zeigten 
hohe Kristallinität, hohe Sättigungsmagnetisierung d superparamagnetisches Verhalten. Die 
polymerbeschichteten Nanopartikel waren eng verteilt um einen mittleren Durchmesser von 
40 nm und verfügten über Relaxationsparameter, die vergleichbar zu denen derzeit auf dem 
Markt verwendeter Produkte sind. In Anbetracht der Ergebnisse erscheinen die hergestellten 
ferrofluidischen Nanosuspensionen interessant für eine intrakorporale Anwendung als 
Kontrastmittel für die MRT. 
In Kapitel 3 werden entgegengesetzt geladene Nanopartikelsysteme im Hinblick auf ihre 
physikochemischen Eigenschaften, Zellaufnahme und Relaxometrie untersucht. Die 
Ergebnisse dieses Abschnitts bestätigen, dass die Ob rflächenladung magnetischer 
Eisenoxidnanopartikel entscheidenden Einfluss auf deren Zellinternalisierung hat. Die 
Aufnahme nach 24 Stunden lag für Partikel mit positivem Zetapotential fast zehnmal so hoch 
wie für negative Partikel und erfolgte zudem mit schnellerer Kinetik. Grundsätzlich bestätigen 
die Ergebnisse unsere Annahme der schnelleren Aufnahme positiver Trägersysteme aufgrund 
der elektrostatischen Anziehung durch die Zellmembran. Der deutliche Unterschied in den 
absoluten Aufnahmeraten der beiden Systeme ließ allerdings vermuten, dass weitere 
synergistische Effekte, wie zum Beispiel die Kolloidstabilität, zur Zellinternalisierung 
beitragen. Beide untersuchten Systeme waren nach ihrer Aufnahme in zellulären Endosomen 
lokalisiert. Der Einschluss in endosomalen Kompartimenten führte zu einer Änderung der 
Relaxationseigenschaften im Gegensatz zu frei vorliegenden Nanosuspensionen. Zudem 
schwächte sich der Signalkontrast in T2-gewichteten MRT-Sequenzen ab. Nichtsdestotrotz 
bewirkten Zellphantome nach Inkubation mit positiv geladenen Nanopartikeln ausgeprägten 
Kontrast in diesen Sequenzen. Die Ergebnisse deuten an, dass die untersuchten positiv 
geladenen Nanosuspensionen geeignete Kontrastmittel auf dem Gebiet der Zellverfolgung 
darstellen können, da dort umfassende Aufnahme und a sgeprägte Relaxivität gefordert sind. 





Die Herstellung eines neuartigen Ferrofluids auf Basis von Eisenoxid und Polyethylenimin-g-
Polyethylenglykol wurde erfolgreich durchgeführt, und sein generelles Potential für 
biomedizinische Anwendungen aufgezeigt. Die geschaffene Plattform ermöglicht eine 
Fortsetzung der Studien in verschiedene Richtungen. Unter den vielen Optionen stellt die in 
vivo Testung der Formulierung die sinnvollste Möglichkeit dar. In diesem Zusammenhang 
könnte die Bioverteilung nach intravenöser Applikation untersucht werden, um die 
Akkumulation in anderen Geweben als der Leber zu beleuchten. Im Fall, dass der Großteil der 
magnetischen Nanopartikel doch in der Leber angesammelt wird, kann eine Anwendung für 
die Detektion fokaler Läsionen in Betracht gezogen w rden. Die meisten vermarkteten MRT-
Kontrastmittel sind aufgrund ihrer fehlenden Selektivität für diese Indikation zugelassen. Das 
Ziel für die Zukunft muss es sein, ein ausreichendes Maß an Tumorselektivität zu erreichen. 
Eine seit Jahren diskutierte Methode ist das Anbringen kleiner Moleküle (small molecules) 
und anderer zielgerichteter Reste an Nanopartikel. Für die genannten Partikel wäre eine 
derartige Funktionalisierung relativ leicht, da dieintrinsisch vorhandenen PEG-Moleküle als 
Linker verwendet werden können. Je nach Wahl der Funktionalität würden sich künstliche 
subkutane Tumoren in ihrer Aufnahmefähigkeit für unterschiedlich modifizierte Systeme 
unterscheiden und müssten folglich differenziert abbild ar sein. Bezüglich der Zellverfolgung 
wäre es interessant, den maximalen Beladungsgrad verschi dener Zelltypen mit 
ferrofluidischen Nanopartikeln zu ermitteln. Hierbei ist eine natürliche Grenze durch die 
zytotoxischen Nebenwirkungen gegeben. 
Neben der Anwendung auf dem Gebiet der MRT können Frrofluide auch für die 
Hyperthermiebehandlung eingesetzt werden. Nachdem Zellen mit magnetischen 




























ANOVA  Analysis of Variance 
CT   Computed tomography 
DLS   Dynamic light scattering 
DMEM  Dulbecco’s modified eagle medium 
EGFR   Epidermal growth factor receptor 
EPR   Enhanced permeation and retention 
FCS   Fetal calf serum 
FDA   Food and drug administration 
IC50   Inhibitory concentration 50 percent 
ICP-OES  Inductively coupled plasma optical emission spectrometry 
IONP   Iron oxide nanoparticles 
IR   Infrared spectroscopy 
LDA   Laser Doppler anemometry 
MFI   Mean fluorescence intensity 
MNP   Magnetic nanoparticles 
MPS   Mononuclear phagocytic system 
MR   Magnetic resonance 
MRI   Magnetic resonance imaging 
MWCO  Molecular weight cut-off 
PBP   P-Selectin binding peptide 
PBS   Phosphate buffered saline 
PDI   Polydispersity index 
PEG   Poly(ethylene glycol) / Poly(ethylene oxide) 
PEI   Poly(ethylene imine) 
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PET   Positron emission tomography 
PMA   Poly(maleic anhydride) 
RF   Radiofrequency 
ROI   Region of Interest 
SAR   Specific absorption rate 
SPECT  Single photon emission computed tomography 
SPION  Superparamagnetic iron oxide nanoparticles 
SQUID  Superconducting quantum interference device 
TEM   Transmission electron microscopy 
TGA   Thermal gravimetric analysis 
USPIO  Ultrasmall superparamagnetic iron oxide 
VSM   Vibrating sample magnetometer 
XRD   X-ray diffraction 
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